Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3117068,duration of action,The duration of action of orally administered GTN in the dog depended on the concentration used and was between 15 and 360 min.,[The pharmacology and pharmacokinetics of glycerol-2-nitrate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3117068/),min,15 and 360,1924,DB00883,Isosorbide Dinitrate
,3117068,half-life of elimination,"The half-life of elimination of G-2-N in the rat came to 2 h, and the substance was 100% bioavailable.",[The pharmacology and pharmacokinetics of glycerol-2-nitrate]. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3117068/),h,2,1925,DB00883,Isosorbide Dinitrate
,6642789,peak drug concentrations,"Means of peak drug concentrations of ISDN, 2-ISMN, and 5-ISMN after administration of the 20-mg sustained-release formulation were 5.5, 24.4, and 129.1 ng/ml, respectively, at 3.1, 4.2, and 4.5 h; after the 40-mg sustained-release formulation, they were 10.9, 44.0, and 214.5 ng/ml, respectively, at 4.2, 6.3, and 6.7 h; and after the 20-mg standard formulation, they were 19.1, 34.7, and 159.2 ng/ml, respectively, at 0.5, 1.0, and 1.5 h.",Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6642789/),[ng] / [ml],5.5,2461,DB00883,Isosorbide Dinitrate
,6642789,peak drug concentrations,"Means of peak drug concentrations of ISDN, 2-ISMN, and 5-ISMN after administration of the 20-mg sustained-release formulation were 5.5, 24.4, and 129.1 ng/ml, respectively, at 3.1, 4.2, and 4.5 h; after the 40-mg sustained-release formulation, they were 10.9, 44.0, and 214.5 ng/ml, respectively, at 4.2, 6.3, and 6.7 h; and after the 20-mg standard formulation, they were 19.1, 34.7, and 159.2 ng/ml, respectively, at 0.5, 1.0, and 1.5 h.",Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6642789/),[ng] / [ml],24.4,2462,DB00883,Isosorbide Dinitrate
,6642789,peak drug concentrations,"Means of peak drug concentrations of ISDN, 2-ISMN, and 5-ISMN after administration of the 20-mg sustained-release formulation were 5.5, 24.4, and 129.1 ng/ml, respectively, at 3.1, 4.2, and 4.5 h; after the 40-mg sustained-release formulation, they were 10.9, 44.0, and 214.5 ng/ml, respectively, at 4.2, 6.3, and 6.7 h; and after the 20-mg standard formulation, they were 19.1, 34.7, and 159.2 ng/ml, respectively, at 0.5, 1.0, and 1.5 h.",Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6642789/),[ng] / [ml],129.1,2463,DB00883,Isosorbide Dinitrate
,6642789,peak drug concentrations,"Means of peak drug concentrations of ISDN, 2-ISMN, and 5-ISMN after administration of the 20-mg sustained-release formulation were 5.5, 24.4, and 129.1 ng/ml, respectively, at 3.1, 4.2, and 4.5 h; after the 40-mg sustained-release formulation, they were 10.9, 44.0, and 214.5 ng/ml, respectively, at 4.2, 6.3, and 6.7 h; and after the 20-mg standard formulation, they were 19.1, 34.7, and 159.2 ng/ml, respectively, at 0.5, 1.0, and 1.5 h.",Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6642789/),[ng] / [ml],10.9,2464,DB00883,Isosorbide Dinitrate
,6642789,peak drug concentrations,"Means of peak drug concentrations of ISDN, 2-ISMN, and 5-ISMN after administration of the 20-mg sustained-release formulation were 5.5, 24.4, and 129.1 ng/ml, respectively, at 3.1, 4.2, and 4.5 h; after the 40-mg sustained-release formulation, they were 10.9, 44.0, and 214.5 ng/ml, respectively, at 4.2, 6.3, and 6.7 h; and after the 20-mg standard formulation, they were 19.1, 34.7, and 159.2 ng/ml, respectively, at 0.5, 1.0, and 1.5 h.",Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6642789/),[ng] / [ml],44.0,2465,DB00883,Isosorbide Dinitrate
,6642789,peak drug concentrations,"Means of peak drug concentrations of ISDN, 2-ISMN, and 5-ISMN after administration of the 20-mg sustained-release formulation were 5.5, 24.4, and 129.1 ng/ml, respectively, at 3.1, 4.2, and 4.5 h; after the 40-mg sustained-release formulation, they were 10.9, 44.0, and 214.5 ng/ml, respectively, at 4.2, 6.3, and 6.7 h; and after the 20-mg standard formulation, they were 19.1, 34.7, and 159.2 ng/ml, respectively, at 0.5, 1.0, and 1.5 h.",Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6642789/),[ng] / [ml],214.5,2466,DB00883,Isosorbide Dinitrate
,6642789,peak drug concentrations,"Means of peak drug concentrations of ISDN, 2-ISMN, and 5-ISMN after administration of the 20-mg sustained-release formulation were 5.5, 24.4, and 129.1 ng/ml, respectively, at 3.1, 4.2, and 4.5 h; after the 40-mg sustained-release formulation, they were 10.9, 44.0, and 214.5 ng/ml, respectively, at 4.2, 6.3, and 6.7 h; and after the 20-mg standard formulation, they were 19.1, 34.7, and 159.2 ng/ml, respectively, at 0.5, 1.0, and 1.5 h.",Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6642789/),[ng] / [ml],19.1,2467,DB00883,Isosorbide Dinitrate
,6642789,peak drug concentrations,"Means of peak drug concentrations of ISDN, 2-ISMN, and 5-ISMN after administration of the 20-mg sustained-release formulation were 5.5, 24.4, and 129.1 ng/ml, respectively, at 3.1, 4.2, and 4.5 h; after the 40-mg sustained-release formulation, they were 10.9, 44.0, and 214.5 ng/ml, respectively, at 4.2, 6.3, and 6.7 h; and after the 20-mg standard formulation, they were 19.1, 34.7, and 159.2 ng/ml, respectively, at 0.5, 1.0, and 1.5 h.",Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6642789/),[ng] / [ml],34.7,2468,DB00883,Isosorbide Dinitrate
,6642789,peak drug concentrations,"Means of peak drug concentrations of ISDN, 2-ISMN, and 5-ISMN after administration of the 20-mg sustained-release formulation were 5.5, 24.4, and 129.1 ng/ml, respectively, at 3.1, 4.2, and 4.5 h; after the 40-mg sustained-release formulation, they were 10.9, 44.0, and 214.5 ng/ml, respectively, at 4.2, 6.3, and 6.7 h; and after the 20-mg standard formulation, they were 19.1, 34.7, and 159.2 ng/ml, respectively, at 0.5, 1.0, and 1.5 h.",Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6642789/),[ng] / [ml],159.2,2469,DB00883,Isosorbide Dinitrate
,6642789,half-lives,Reasons are discussed for the biphasic decline of plasma ISDN concentrations (half-lives 26 min and 5.1 h) obtained after administration of the standard-release formulation.,Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6642789/),min,26,2470,DB00883,Isosorbide Dinitrate
,6642789,half-lives,Reasons are discussed for the biphasic decline of plasma ISDN concentrations (half-lives 26 min and 5.1 h) obtained after administration of the standard-release formulation.,Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6642789/),h,5.1,2471,DB00883,Isosorbide Dinitrate
,9281301,relative bioavailability,The relative bioavailability with respect to a reference preparation for AUC related to isosorbide dinitrate was 107.5% and for Cmax 112.5%.,[Study of the bioequivalence of a new isosorbide dinitrate tablet formulation compared with the standard preparation]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9281301/),%,107.5,5795,DB00883,Isosorbide Dinitrate
,9281301,relative bioavailability,The relative bioavailability with respect to a reference preparation for AUC related to isosorbide dinitrate was 107.5% and for Cmax 112.5%.,[Study of the bioequivalence of a new isosorbide dinitrate tablet formulation compared with the standard preparation]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9281301/),%,112.5,5796,DB00883,Isosorbide Dinitrate
,7873466,half-life,"Isosorbide 5-mononitrate has been studied in its own right as an antianginal agent: it is completely absorbed after oral administration; it has a half-life of around 4 hours, and oral standard and controlled-release formulations have been extensively studied.",Clinical pharmacokinetics of nitrates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7873466/),h,4,11964,DB00883,Isosorbide Dinitrate
,1578380,half-lives,"Using this pharmacodynamic model, the in vivo half-lives of nitric oxide and cGMP were estimated to be 1.6 and 2.0 min, respectively.",Pharmacokinetic/pharmacodynamic relationship of the duration of vasodilating action of organic mononitrates in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1578380/),min,1.6,17451,DB00883,Isosorbide Dinitrate
,1578380,half-lives,"Using this pharmacodynamic model, the in vivo half-lives of nitric oxide and cGMP were estimated to be 1.6 and 2.0 min, respectively.",Pharmacokinetic/pharmacodynamic relationship of the duration of vasodilating action of organic mononitrates in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1578380/),min,2.0,17452,DB00883,Isosorbide Dinitrate
,4005392,bioavailability,"The comparative bioavailability of isosorbide dinitrate, isosorbide 2-nitrate and isosorbide 5-nitrate from the sustained-release tablet was 110 per cent (p greater than 0.05), 89 per cent (p greater than 0.05), and 89 per cent (p less than 0.05), respectively, of that from the reference standard-release tablet.",Bioequivalence of a sustained-release isosorbide dinitrate formulation at steady-state. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4005392/),%,110,18529,DB00883,Isosorbide Dinitrate
,4005392,bioavailability,"The comparative bioavailability of isosorbide dinitrate, isosorbide 2-nitrate and isosorbide 5-nitrate from the sustained-release tablet was 110 per cent (p greater than 0.05), 89 per cent (p greater than 0.05), and 89 per cent (p less than 0.05), respectively, of that from the reference standard-release tablet.",Bioequivalence of a sustained-release isosorbide dinitrate formulation at steady-state. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4005392/),%,89,18530,DB00883,Isosorbide Dinitrate
,1530422,minimal concentration,"The concentrations measured enabled the study of the pharmacokinetics of this new form, showing an average minimal concentration of 5-isosorbide mononitrate (principal metabolite) of 85 +/- 41 micrograms/l and an amplitude of fluctuation over the 24 hours period of 296 +/- 102 micrograms/l.",[Pharmacokinetics and pharmacodynamics of a new 80 mg oral delayed-action isosorbide dinitrate preparation]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530422/),[Î¼g] / [l],85,19215,DB00883,Isosorbide Dinitrate
,1530422,amplitude of,"The concentrations measured enabled the study of the pharmacokinetics of this new form, showing an average minimal concentration of 5-isosorbide mononitrate (principal metabolite) of 85 +/- 41 micrograms/l and an amplitude of fluctuation over the 24 hours period of 296 +/- 102 micrograms/l.",[Pharmacokinetics and pharmacodynamics of a new 80 mg oral delayed-action isosorbide dinitrate preparation]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530422/),[Î¼g] / [l],29,19216,DB00883,Isosorbide Dinitrate
,7614524,peak plasma concentrations,"After oral administration of extended-release 5-ISMN 60 mg or 120 mg once daily, 5-ISMN was slowly absorbed, reaching mean peak plasma concentrations of 557 and 1151 ng/mL, respectively, in approximately 3 hours.",Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614524/),[ng] / [ml],557,20439,DB00883,Isosorbide Dinitrate
,7614524,peak plasma concentrations,"After oral administration of extended-release 5-ISMN 60 mg or 120 mg once daily, 5-ISMN was slowly absorbed, reaching mean peak plasma concentrations of 557 and 1151 ng/mL, respectively, in approximately 3 hours.",Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614524/),[ng] / [ml],1151,20440,DB00883,Isosorbide Dinitrate
,7614524,peak plasma 5-ISMN concentration,"After oral administration of ISDN 40 mg every 6 hours, a mean peak plasma 5-ISMN concentration of 806 ng/mL was achieved in less than 2 hours (mean time to reach the maximum plasma concentration was 1.5 hours).",Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614524/),[ng] / [ml],806,20441,DB00883,Isosorbide Dinitrate
,7614524,time to reach the maximum plasma concentration,"After oral administration of ISDN 40 mg every 6 hours, a mean peak plasma 5-ISMN concentration of 806 ng/mL was achieved in less than 2 hours (mean time to reach the maximum plasma concentration was 1.5 hours).",Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614524/),h,1.5,20442,DB00883,Isosorbide Dinitrate
,7614524,plasma apparent elimination half-life,The mean plasma apparent elimination half-life of 5-ISMN was 6.2 hours after extended-release 5-ISMN administration and 7.1 hours after ISDN.,Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614524/),h,6.2,20443,DB00883,Isosorbide Dinitrate
,7614524,plasma apparent elimination half-life,The mean plasma apparent elimination half-life of 5-ISMN was 6.2 hours after extended-release 5-ISMN administration and 7.1 hours after ISDN.,Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614524/),h,7.1,20444,DB00883,Isosorbide Dinitrate
,15146932,AUC0-t,"AUC0-t and AUC0-infinity of 5-ISMN tablet and intravenous infusion were 2694 +/- 496 ng x ml(-1) x h vs. 2548 +/- 556 ng x ml(-1) x h and 3266 +/- 624 ng x ml(-1) x h vs. 3178 +/- 769 ng x ml(-1) x h, respectively, and the relative bioavailability of 5-ISMN tablet was 105 +/- 20%.",Pharmacokinetics of three organic nitrates in Chinese healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15146932/),[hÂ·ng] / [ml],2694,22301,DB00883,Isosorbide Dinitrate
,15146932,AUC0-t,"AUC0-t and AUC0-infinity of 5-ISMN tablet and intravenous infusion were 2694 +/- 496 ng x ml(-1) x h vs. 2548 +/- 556 ng x ml(-1) x h and 3266 +/- 624 ng x ml(-1) x h vs. 3178 +/- 769 ng x ml(-1) x h, respectively, and the relative bioavailability of 5-ISMN tablet was 105 +/- 20%.",Pharmacokinetics of three organic nitrates in Chinese healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15146932/),[hÂ·ng] / [ml],2548,22302,DB00883,Isosorbide Dinitrate
,15146932,AUC0-infinity,"AUC0-t and AUC0-infinity of 5-ISMN tablet and intravenous infusion were 2694 +/- 496 ng x ml(-1) x h vs. 2548 +/- 556 ng x ml(-1) x h and 3266 +/- 624 ng x ml(-1) x h vs. 3178 +/- 769 ng x ml(-1) x h, respectively, and the relative bioavailability of 5-ISMN tablet was 105 +/- 20%.",Pharmacokinetics of three organic nitrates in Chinese healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15146932/),[hÂ·ng] / [ml],3266,22303,DB00883,Isosorbide Dinitrate
,15146932,AUC0-infinity,"AUC0-t and AUC0-infinity of 5-ISMN tablet and intravenous infusion were 2694 +/- 496 ng x ml(-1) x h vs. 2548 +/- 556 ng x ml(-1) x h and 3266 +/- 624 ng x ml(-1) x h vs. 3178 +/- 769 ng x ml(-1) x h, respectively, and the relative bioavailability of 5-ISMN tablet was 105 +/- 20%.",Pharmacokinetics of three organic nitrates in Chinese healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15146932/),[hÂ·ng] / [ml],3178,22304,DB00883,Isosorbide Dinitrate
,15146932,relative bioavailability,"AUC0-t and AUC0-infinity of 5-ISMN tablet and intravenous infusion were 2694 +/- 496 ng x ml(-1) x h vs. 2548 +/- 556 ng x ml(-1) x h and 3266 +/- 624 ng x ml(-1) x h vs. 3178 +/- 769 ng x ml(-1) x h, respectively, and the relative bioavailability of 5-ISMN tablet was 105 +/- 20%.",Pharmacokinetics of three organic nitrates in Chinese healthy male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15146932/),%,105,22305,DB00883,Isosorbide Dinitrate
,2033915,peak concentration,As compared to subjects with normal CVP patients with hemodynamic impairment showed a markedly lower peak concentration of isosorbide-5-mononitrate levels (475 +/- 32 vs 663 +/- 38 ngml-1; p less than 0.01; mean +/- SEM) which occurred delayed (32 +/- 6 vs 55 +/- 9 s; p less than 0.05).,Pharmacokinetics of oral isosorbide-5-mononitrate in patients with ischemic heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2033915/),1/[ngml],475,27215,DB00883,Isosorbide Dinitrate
,2033915,peak concentration,As compared to subjects with normal CVP patients with hemodynamic impairment showed a markedly lower peak concentration of isosorbide-5-mononitrate levels (475 +/- 32 vs 663 +/- 38 ngml-1; p less than 0.01; mean +/- SEM) which occurred delayed (32 +/- 6 vs 55 +/- 9 s; p less than 0.05).,Pharmacokinetics of oral isosorbide-5-mononitrate in patients with ischemic heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2033915/),1/[ngml],663,27216,DB00883,Isosorbide Dinitrate
,2033915,peak concentration,As compared to subjects with normal CVP patients with hemodynamic impairment showed a markedly lower peak concentration of isosorbide-5-mononitrate levels (475 +/- 32 vs 663 +/- 38 ngml-1; p less than 0.01; mean +/- SEM) which occurred delayed (32 +/- 6 vs 55 +/- 9 s; p less than 0.05).,Pharmacokinetics of oral isosorbide-5-mononitrate in patients with ischemic heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2033915/),,55,27217,DB00883,Isosorbide Dinitrate
,2033915,elimination rate constant,Reduced cardiac function also resulted in a prolonged elimination of isosorbide-5-mononitrate as was suggested by the diminished elimination rate constant (0.14 +/- 0.01 vs 0.18 +/- 0.01 h-1; p less than 0.05).,Pharmacokinetics of oral isosorbide-5-mononitrate in patients with ischemic heart failure. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2033915/),1/[h],0.14,27218,DB00883,Isosorbide Dinitrate
,2033915,elimination rate constant,Reduced cardiac function also resulted in a prolonged elimination of isosorbide-5-mononitrate as was suggested by the diminished elimination rate constant (0.14 +/- 0.01 vs 0.18 +/- 0.01 h-1; p less than 0.05).,Pharmacokinetics of oral isosorbide-5-mononitrate in patients with ischemic heart failure. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2033915/),1/[h],0.18,27219,DB00883,Isosorbide Dinitrate
,1418058,apparent steady state volume,"After the intravenous dose, the apparent steady state volume of ISDN distribution came to 179.9 l, total body clearance was 3.14 l min-1, and terminal half-life was 79 min, on average.",Bioavailability and metabolism of isosorbide dinitrate from a transdermal spray. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418058/),l,179.9,31312,DB00883,Isosorbide Dinitrate
,1418058,total body clearance,"After the intravenous dose, the apparent steady state volume of ISDN distribution came to 179.9 l, total body clearance was 3.14 l min-1, and terminal half-life was 79 min, on average.",Bioavailability and metabolism of isosorbide dinitrate from a transdermal spray. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418058/),[l] / [min],3.14,31313,DB00883,Isosorbide Dinitrate
,1418058,terminal half-life,"After the intravenous dose, the apparent steady state volume of ISDN distribution came to 179.9 l, total body clearance was 3.14 l min-1, and terminal half-life was 79 min, on average.",Bioavailability and metabolism of isosorbide dinitrate from a transdermal spray. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418058/),min,79,31314,DB00883,Isosorbide Dinitrate
,1418058,peak plasma concentration,The transdermal absorption resulted in an average peak plasma concentration of 6.9 ng ISDN ml-1 at 5 h after the administration.,Bioavailability and metabolism of isosorbide dinitrate from a transdermal spray. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418058/),[isdnÂ·ng] / [ml],6.9,31315,DB00883,Isosorbide Dinitrate
,3675680,peak plasma levels,"Pharmacokinetic data showed that the sustained release formulation reached significantly lower and delayed mean peak plasma levels compared with the conventional formulation, respectively 452.8 +/- 67.8 ng/ml and 706.7 +/- 57.3 (mean +/- SE) (p less than 0.05).",Pharmacokinetics of isosorbide mononitrate in a new sustained release oral form in comparison with a conventional formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675680/),[ng] / [ml],452.8,31471,DB00883,Isosorbide Dinitrate
,3675680,peak plasma levels,"Pharmacokinetic data showed that the sustained release formulation reached significantly lower and delayed mean peak plasma levels compared with the conventional formulation, respectively 452.8 +/- 67.8 ng/ml and 706.7 +/- 57.3 (mean +/- SE) (p less than 0.05).",Pharmacokinetics of isosorbide mononitrate in a new sustained release oral form in comparison with a conventional formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675680/),,706.7,31472,DB00883,Isosorbide Dinitrate
,3675680,Peak times,"Peak times were 4.6 +/- 0.2 and 2.4 +/- 0.2 (p less than 0.005) h, respectively.",Pharmacokinetics of isosorbide mononitrate in a new sustained release oral form in comparison with a conventional formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675680/),h,4.6,31473,DB00883,Isosorbide Dinitrate
,3675680,Peak times,"Peak times were 4.6 +/- 0.2 and 2.4 +/- 0.2 (p less than 0.005) h, respectively.",Pharmacokinetics of isosorbide mononitrate in a new sustained release oral form in comparison with a conventional formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675680/),h,2.4,31474,DB00883,Isosorbide Dinitrate
,3987768,elimination half-lives,"The median elimination half-lives of ISDN, IS-5-MN, IS-2-MN and IS-5-MN-2-Glu were 0.7, 5.1, 3.2 and 2.5 h, respectively.",Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987768/),h,0.7,34021,DB00883,Isosorbide Dinitrate
,3987768,elimination half-lives,"The median elimination half-lives of ISDN, IS-5-MN, IS-2-MN and IS-5-MN-2-Glu were 0.7, 5.1, 3.2 and 2.5 h, respectively.",Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987768/),h,5.1,34022,DB00883,Isosorbide Dinitrate
,3987768,elimination half-lives,"The median elimination half-lives of ISDN, IS-5-MN, IS-2-MN and IS-5-MN-2-Glu were 0.7, 5.1, 3.2 and 2.5 h, respectively.",Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987768/),h,3.2,34023,DB00883,Isosorbide Dinitrate
,3987768,elimination half-lives,"The median elimination half-lives of ISDN, IS-5-MN, IS-2-MN and IS-5-MN-2-Glu were 0.7, 5.1, 3.2 and 2.5 h, respectively.",Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987768/),h,2.5,34024,DB00883,Isosorbide Dinitrate
,3987768,systemic clearance,The systemic clearance of ISDN was 3.71/min and the distribution volume 2521 (3.1 l/kg).,Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987768/),1/[min],3.71,34025,DB00883,Isosorbide Dinitrate
,3987768,distribution volume,The systemic clearance of ISDN was 3.71/min and the distribution volume 2521 (3.1 l/kg).,Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987768/),[l] / [kg],2521,34026,DB00883,Isosorbide Dinitrate
,3987768,distribution volume,The systemic clearance of ISDN was 3.71/min and the distribution volume 2521 (3.1 l/kg).,Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987768/),[l] / [kg],3.1,34027,DB00883,Isosorbide Dinitrate
,3987768,renal clearance,"Apart from IS-5-MN-2-Glu, with a renal clearance of 5.9 l/min which suggested substantial glucuronidation in the kidney, the renal clearances of ISDN, IS-5-MN, IS-2-MN and the corresponding amounts excreted were negligible.",Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987768/),[l] / [min],5.9,34028,DB00883,Isosorbide Dinitrate
,9150853,m/z,"The detected masses were m/z 324 for PE-di-N, m/z 351 for PE-mono-N and m/z 217 for IS-5-MN.",Quantitative determination of pentaerythrityl tetranitrate and its metabolites in human plasma by gas chromatography/mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9150853/),,324,40460,DB00883,Isosorbide Dinitrate
,9150853,m/z,"The detected masses were m/z 324 for PE-di-N, m/z 351 for PE-mono-N and m/z 217 for IS-5-MN.",Quantitative determination of pentaerythrityl tetranitrate and its metabolites in human plasma by gas chromatography/mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9150853/),,351,40461,DB00883,Isosorbide Dinitrate
,9150853,m/z,"The detected masses were m/z 324 for PE-di-N, m/z 351 for PE-mono-N and m/z 217 for IS-5-MN.",Quantitative determination of pentaerythrityl tetranitrate and its metabolites in human plasma by gas chromatography/mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9150853/),,217,40462,DB00883,Isosorbide Dinitrate
over,9150853,maximum concentration,The maximum concentration of these analytes in the subject samples were on the average all over 5 ng/ml plasma after the oral administration of 100 mg PETN.,Quantitative determination of pentaerythrityl tetranitrate and its metabolites in human plasma by gas chromatography/mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9150853/),[ng] / [ml],5,40463,DB00883,Isosorbide Dinitrate
,1233213,peak concentrations,"The peak concentrations found were 4.5, 11.7 and 34.3 ng/ml of isosorbide dinitrate, isosorbide 2-mononitrate and isosorbide 5-mononitrate, respectively, in the blood of one subject and 5.9, 15 and 61.3 ng/ml, respectively, in the blood of another subject.",Concentrations of the vasodilator isosorbide dinitrate and its metabolites in the blood of human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233213/),[ng] / [ml],4.5,40628,DB00883,Isosorbide Dinitrate
,1233213,peak concentrations,"The peak concentrations found were 4.5, 11.7 and 34.3 ng/ml of isosorbide dinitrate, isosorbide 2-mononitrate and isosorbide 5-mononitrate, respectively, in the blood of one subject and 5.9, 15 and 61.3 ng/ml, respectively, in the blood of another subject.",Concentrations of the vasodilator isosorbide dinitrate and its metabolites in the blood of human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233213/),[ng] / [ml],11.7,40629,DB00883,Isosorbide Dinitrate
,1233213,peak concentrations,"The peak concentrations found were 4.5, 11.7 and 34.3 ng/ml of isosorbide dinitrate, isosorbide 2-mononitrate and isosorbide 5-mononitrate, respectively, in the blood of one subject and 5.9, 15 and 61.3 ng/ml, respectively, in the blood of another subject.",Concentrations of the vasodilator isosorbide dinitrate and its metabolites in the blood of human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233213/),[ng] / [ml],34.3,40630,DB00883,Isosorbide Dinitrate
,1233213,peak concentrations,"The peak concentrations found were 4.5, 11.7 and 34.3 ng/ml of isosorbide dinitrate, isosorbide 2-mononitrate and isosorbide 5-mononitrate, respectively, in the blood of one subject and 5.9, 15 and 61.3 ng/ml, respectively, in the blood of another subject.",Concentrations of the vasodilator isosorbide dinitrate and its metabolites in the blood of human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233213/),[ng] / [ml],5.9,40631,DB00883,Isosorbide Dinitrate
,1233213,peak concentrations,"The peak concentrations found were 4.5, 11.7 and 34.3 ng/ml of isosorbide dinitrate, isosorbide 2-mononitrate and isosorbide 5-mononitrate, respectively, in the blood of one subject and 5.9, 15 and 61.3 ng/ml, respectively, in the blood of another subject.",Concentrations of the vasodilator isosorbide dinitrate and its metabolites in the blood of human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233213/),[ng] / [ml],15,40632,DB00883,Isosorbide Dinitrate
,1233213,peak concentrations,"The peak concentrations found were 4.5, 11.7 and 34.3 ng/ml of isosorbide dinitrate, isosorbide 2-mononitrate and isosorbide 5-mononitrate, respectively, in the blood of one subject and 5.9, 15 and 61.3 ng/ml, respectively, in the blood of another subject.",Concentrations of the vasodilator isosorbide dinitrate and its metabolites in the blood of human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233213/),[ng] / [ml],61.3,40633,DB00883,Isosorbide Dinitrate
,7710435,peak concentration,The two oral preparations led to peak concentration values of about 360 ng/ml of IS-5-MN in the mean 0.90 h (treatment A) and 0.97 h (treatment B) after drug administration.,Evaluation of the pharmacokinetics and absolute bioavailability of three isosorbide-5-mononitrate preparations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710435/),[ng] / [ml],360,43957,DB00883,Isosorbide Dinitrate
,7710435,areas under the curve (AUC(0-infinity)),For the areas under the curve (AUC(0-infinity)) mean values of 2733 (treatment A).,Evaluation of the pharmacokinetics and absolute bioavailability of three isosorbide-5-mononitrate preparations in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710435/),,2733,43958,DB00883,Isosorbide Dinitrate
,7710435,absolute bioavailability,"The absolute bioavailability of both oral treatments revealed values of 95.00% and 94.74% for treatments A and B, respectively.",Evaluation of the pharmacokinetics and absolute bioavailability of three isosorbide-5-mononitrate preparations in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710435/),%,95.00,43959,DB00883,Isosorbide Dinitrate
,7710435,absolute bioavailability,"The absolute bioavailability of both oral treatments revealed values of 95.00% and 94.74% for treatments A and B, respectively.",Evaluation of the pharmacokinetics and absolute bioavailability of three isosorbide-5-mononitrate preparations in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710435/),%,94.74,43960,DB00883,Isosorbide Dinitrate
,6713775,systemic clearance,"Mean (+/- SD) systemic clearance of 5-ISMN was 127 +/- 21 ml/min, volume of distribution was 48.5 +/- 6.1 l, t 1/2 was 4.4 +/- 0.5 hr, and mean residence time was 6.2 +/- 0.7 hr.",Isosorbide 5-mononitrate kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713775/),[ml] / [min],127,44530,DB00883,Isosorbide Dinitrate
,6713775,volume of distribution,"Mean (+/- SD) systemic clearance of 5-ISMN was 127 +/- 21 ml/min, volume of distribution was 48.5 +/- 6.1 l, t 1/2 was 4.4 +/- 0.5 hr, and mean residence time was 6.2 +/- 0.7 hr.",Isosorbide 5-mononitrate kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713775/),l,48.5,44531,DB00883,Isosorbide Dinitrate
,6713775,t 1/2,"Mean (+/- SD) systemic clearance of 5-ISMN was 127 +/- 21 ml/min, volume of distribution was 48.5 +/- 6.1 l, t 1/2 was 4.4 +/- 0.5 hr, and mean residence time was 6.2 +/- 0.7 hr.",Isosorbide 5-mononitrate kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713775/),h,4.4,44532,DB00883,Isosorbide Dinitrate
,6713775,mean residence time,"Mean (+/- SD) systemic clearance of 5-ISMN was 127 +/- 21 ml/min, volume of distribution was 48.5 +/- 6.1 l, t 1/2 was 4.4 +/- 0.5 hr, and mean residence time was 6.2 +/- 0.7 hr.",Isosorbide 5-mononitrate kinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713775/),h,6.2,44533,DB00883,Isosorbide Dinitrate
,6713775,plasma drug concentrations,"At the end of intravenous infusion of 5-ISMN at a rate of 8 mg/hr for 2.5 hr, mean plasma drug concentrations reached 356 +/- 39 ng/ml.",Isosorbide 5-mononitrate kinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713775/),[ng] / [ml],356,44534,DB00883,Isosorbide Dinitrate
,6713775,systemic availability,"Oral doses of 5-ISMN were essentially completely absorbed (93% +/- 13% systemic availability), and mean peak plasma drug concentrations of 388 +/- 70 ng/ml occurred at 0.83 +/- 0.46 hr.",Isosorbide 5-mononitrate kinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713775/),%,93,44535,DB00883,Isosorbide Dinitrate
,6713775,peak plasma drug concentrations,"Oral doses of 5-ISMN were essentially completely absorbed (93% +/- 13% systemic availability), and mean peak plasma drug concentrations of 388 +/- 70 ng/ml occurred at 0.83 +/- 0.46 hr.",Isosorbide 5-mononitrate kinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713775/),[ng] / [ml],388,44536,DB00883,Isosorbide Dinitrate
,6713775,absorption t 1/2,Mean absorption t 1/2 was 19 +/- 12 min.,Isosorbide 5-mononitrate kinetics. ,"t1/2,Î±-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6713775/),min,19,44537,DB00883,Isosorbide Dinitrate
,1530423,trough concentration,"Both achieved the required trough concentration to restore sensitivity to nitrates (100 micrograms/l for IS-5MN), but greater plasma level increases were observed (greater than 200 micrograms/l for IS-5MN), with 60 mg once daily.",[Nycthemeral changes in plasma concentrations of active nitrate derivatives. Comparison of a single dose of LP 60mg isosobide dinitrate and LP 20mg isosobide dinitrate administered 3 times daily]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1530423/),[Î¼g] / [l],100,46430,DB00883,Isosorbide Dinitrate
,8430056,volumes of distribution,The volumes of distribution were similar for all four isomers and were estimated at about 1.0 liter/kg.,"Pharmacokinetics of stereomeric 1,4:3,6-dianhydrohexitol mononitrates in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430056/),[l] / [kg],1.0,50733,DB00883,Isosorbide Dinitrate
,8430056,systemic clearances,"The systemic clearances of L-IIMN, IMMN, IS-2-MN, and IS-5-MN were 65.1 +/- 13.0, 32.7 +/- 12.0, 11.0 +/- 2.3, and 8.23 +/- 1.82 ml/min/kg, respectively (P < 0.05, all pairwise comparisons).","Pharmacokinetics of stereomeric 1,4:3,6-dianhydrohexitol mononitrates in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430056/),[ml] / [kgÂ·min],65.1,50734,DB00883,Isosorbide Dinitrate
,8430056,systemic clearances,"The systemic clearances of L-IIMN, IMMN, IS-2-MN, and IS-5-MN were 65.1 +/- 13.0, 32.7 +/- 12.0, 11.0 +/- 2.3, and 8.23 +/- 1.82 ml/min/kg, respectively (P < 0.05, all pairwise comparisons).","Pharmacokinetics of stereomeric 1,4:3,6-dianhydrohexitol mononitrates in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430056/),[ml] / [kgÂ·min],32.7,50735,DB00883,Isosorbide Dinitrate
,8430056,systemic clearances,"The systemic clearances of L-IIMN, IMMN, IS-2-MN, and IS-5-MN were 65.1 +/- 13.0, 32.7 +/- 12.0, 11.0 +/- 2.3, and 8.23 +/- 1.82 ml/min/kg, respectively (P < 0.05, all pairwise comparisons).","Pharmacokinetics of stereomeric 1,4:3,6-dianhydrohexitol mononitrates in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430056/),[ml] / [kgÂ·min],11.0,50736,DB00883,Isosorbide Dinitrate
,8430056,systemic clearances,"The systemic clearances of L-IIMN, IMMN, IS-2-MN, and IS-5-MN were 65.1 +/- 13.0, 32.7 +/- 12.0, 11.0 +/- 2.3, and 8.23 +/- 1.82 ml/min/kg, respectively (P < 0.05, all pairwise comparisons).","Pharmacokinetics of stereomeric 1,4:3,6-dianhydrohexitol mononitrates in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430056/),[ml] / [kgÂ·min],8.23,50737,DB00883,Isosorbide Dinitrate
,8430056,clearances,"The clearances of L-IIMN, IS-2-MN, and IS-5-MN at these higher doses were 42.3 +/- 5.7, 6.38 +/- 0.59, and 3.33 +/- 0.62 ml/min/kg, respectively, all significantly less than those found at the 2 mg/kg dose.","Pharmacokinetics of stereomeric 1,4:3,6-dianhydrohexitol mononitrates in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430056/),[ml] / [kgÂ·min],42.3,50738,DB00883,Isosorbide Dinitrate
,8430056,clearances,"The clearances of L-IIMN, IS-2-MN, and IS-5-MN at these higher doses were 42.3 +/- 5.7, 6.38 +/- 0.59, and 3.33 +/- 0.62 ml/min/kg, respectively, all significantly less than those found at the 2 mg/kg dose.","Pharmacokinetics of stereomeric 1,4:3,6-dianhydrohexitol mononitrates in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430056/),[ml] / [kgÂ·min],6.38,50739,DB00883,Isosorbide Dinitrate
,8430056,clearances,"The clearances of L-IIMN, IS-2-MN, and IS-5-MN at these higher doses were 42.3 +/- 5.7, 6.38 +/- 0.59, and 3.33 +/- 0.62 ml/min/kg, respectively, all significantly less than those found at the 2 mg/kg dose.","Pharmacokinetics of stereomeric 1,4:3,6-dianhydrohexitol mononitrates in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430056/),[ml] / [kgÂ·min],3.33,50740,DB00883,Isosorbide Dinitrate
,6430939,apparent in vitro partitioning ratio,"Using this method, we found the apparent in vitro partitioning ratio of ISDN between erythrocyte and plasma in rat and human blood at 37 degrees C to be 0.22 and 0.13, respectively.","Determination of the partitioning, stability, and metabolite formation of isosorbide dinitrate in human and rat blood using an improved gas-liquid chromatographic assay. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6430939/),,0.22,52119,DB00883,Isosorbide Dinitrate
,6430939,apparent in vitro partitioning ratio,"Using this method, we found the apparent in vitro partitioning ratio of ISDN between erythrocyte and plasma in rat and human blood at 37 degrees C to be 0.22 and 0.13, respectively.","Determination of the partitioning, stability, and metabolite formation of isosorbide dinitrate in human and rat blood using an improved gas-liquid chromatographic assay. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6430939/),,0.13,52120,DB00883,Isosorbide Dinitrate
,31212140,Sensitivity,Sensitivity was determined as 25.0 ng/mL for IS 2-MN and 12.4 ng/mL for IS 5-MN in rat and human plasma.,Development and validation of a chiral LC-ESI-MS/MS method for simultaneous determination of the enantiomeric metabolites isosorbide 2-mononitrate and isosorbide 5-mononitrate of isosorbide dinitrate in rat and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31212140/),[ng] / [ml],25.0,55932,DB00883,Isosorbide Dinitrate
,31212140,Sensitivity,Sensitivity was determined as 25.0 ng/mL for IS 2-MN and 12.4 ng/mL for IS 5-MN in rat and human plasma.,Development and validation of a chiral LC-ESI-MS/MS method for simultaneous determination of the enantiomeric metabolites isosorbide 2-mononitrate and isosorbide 5-mononitrate of isosorbide dinitrate in rat and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31212140/),[ng] / [ml],12.4,55933,DB00883,Isosorbide Dinitrate
,6882466,half-life,"The mononitrates were eliminated with a half-life of 30-70 min, giving rise to the completely denitrated product, adenosine-5'-(N-ethyl-carboxamide) (NECA).","Metabolism and disposition of 2',3'-di-O-nitro-adenosine-5'-(N-ethyl-carboxamide) in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882466/),min,30-70,60525,DB00883,Isosorbide Dinitrate
,6882466,half-life,The latter product was not further metabolized and was eliminated with a half-life of about 4 hr.,"Metabolism and disposition of 2',3'-di-O-nitro-adenosine-5'-(N-ethyl-carboxamide) in dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882466/),h,4,60526,DB00883,Isosorbide Dinitrate
,6882466,Urinary excretion,Urinary excretion averaged 50% of the administered dose within 4 days and was represented essentially by the completely denitrated drug.,"Metabolism and disposition of 2',3'-di-O-nitro-adenosine-5'-(N-ethyl-carboxamide) in dogs. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882466/),%,50,60527,DB00883,Isosorbide Dinitrate
,6882466,Oral bioavailability,Oral bioavailability of the drug was about 90%.,"Metabolism and disposition of 2',3'-di-O-nitro-adenosine-5'-(N-ethyl-carboxamide) in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6882466/),%,90,60528,DB00883,Isosorbide Dinitrate
,6134800,apparent elimination half-life,The apparent elimination half-life from serum of 2-ISMN and 5-ISMN was 2-3 h.,Absorption and excretion of isosorbide dinitrate and isosorbide-2-mononitrate in dogs. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6134800/),h,2-3,62081,DB00883,Isosorbide Dinitrate
,6134800,apparent volume of distribution,The apparent volume of distribution of 2-ISMN averaged 8.3 litres.,Absorption and excretion of isosorbide dinitrate and isosorbide-2-mononitrate in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6134800/),l,8.3,62082,DB00883,Isosorbide Dinitrate
,7295882,C.V,"When isosorbide 5-mononitrate was intravenously infused at a rate of 4 mg h-1 for 2.5 h to five human subjects, its concentrations in plasma increased slowly to 185 ng ml-1 +/- 5 per cent C.V. at 2.5 h and a steady-state plasma level was not reached during the infusion.",Isosorbide 5-mononitrate pharmacokinetics in humans. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295882/),[ng] / [ml],185,62668,DB00883,Isosorbide Dinitrate
,7295882,elimination half-life,"When the infusion was discontinued, plasma drug concentrations declined with an elimination half-life of 4.2 h +/- 6 per cent C.V.",Isosorbide 5-mononitrate pharmacokinetics in humans. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295882/),h,4.2,62669,DB00883,Isosorbide Dinitrate
,7295882,systemic clearance,The systemic clearance after the infusion doses was 132 ml min-1 +/- 18 per cent C.V. and the volume of distribution was 48.4 +/- 16 per cent C.V.,Isosorbide 5-mononitrate pharmacokinetics in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295882/),[ml] / [min],132,62670,DB00883,Isosorbide Dinitrate
,7295882,volume of distribution,The systemic clearance after the infusion doses was 132 ml min-1 +/- 18 per cent C.V. and the volume of distribution was 48.4 +/- 16 per cent C.V.,Isosorbide 5-mononitrate pharmacokinetics in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295882/),%,48.4,62671,DB00883,Isosorbide Dinitrate
,7295882,C.V,The systemic clearance after the infusion doses was 132 ml min-1 +/- 18 per cent C.V. and the volume of distribution was 48.4 +/- 16 per cent C.V.,Isosorbide 5-mononitrate pharmacokinetics in humans. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295882/),%,48.4,62672,DB00883,Isosorbide Dinitrate
,7295882,peak plasma isosorbide 5-mononitrate concentration,"After equal oral doses of 10 mg, the peak plasma isosorbide 5-mononitrate concentration of 191 ng ml-1 +/- 16 per cent C.V. was reached at 1.1 h +/- 30 per cent C.V., and plasma levels declined with a terminal half-life of 4.9 h.",Isosorbide 5-mononitrate pharmacokinetics in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295882/),[ng] / [ml],191,62673,DB00883,Isosorbide Dinitrate
,7295882,terminal half-life,"After equal oral doses of 10 mg, the peak plasma isosorbide 5-mononitrate concentration of 191 ng ml-1 +/- 16 per cent C.V. was reached at 1.1 h +/- 30 per cent C.V., and plasma levels declined with a terminal half-life of 4.9 h.",Isosorbide 5-mononitrate pharmacokinetics in humans. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295882/),h,4.9,62674,DB00883,Isosorbide Dinitrate
,7295882,peak plasma concentration,"After single oral doses of 10 mg isosorbide dinitrate, the peak plasma concentration of the 5-mononitrate metabolite of 72 ng ml-1 +/- 27 per cent C. V. occurred at 1.7 h +/- 41 per cent C.V.",Isosorbide 5-mononitrate pharmacokinetics in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295882/),[ng] / [ml],72,62675,DB00883,Isosorbide Dinitrate
,7295882,C.V,"After single oral doses of 10 mg isosorbide dinitrate, the peak plasma concentration of the 5-mononitrate metabolite of 72 ng ml-1 +/- 27 per cent C. V. occurred at 1.7 h +/- 41 per cent C.V.",Isosorbide 5-mononitrate pharmacokinetics in humans. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295882/),h,1.7,62676,DB00883,Isosorbide Dinitrate
,19122316,lag time,"The pellets achieved a lag time of 4.1 h in vivo, which had a good consistency with the in vitro results, and the relative bioavailability was nearly 100% comparing to the normal tablets.",Design and evaluation of pH-independent pulsatile release pellets containing isosorbide-5-mononitrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19122316/),h,4.1,63173,DB00883,Isosorbide Dinitrate
,19122316,relative bioavailability,"The pellets achieved a lag time of 4.1 h in vivo, which had a good consistency with the in vitro results, and the relative bioavailability was nearly 100% comparing to the normal tablets.",Design and evaluation of pH-independent pulsatile release pellets containing isosorbide-5-mononitrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19122316/),%,100,63174,DB00883,Isosorbide Dinitrate
,7182455,Distribution half-life,Distribution half-life was extremely rapid (2-5 min).,Pharmacokinetics of intravenous isosorbide-dinitrate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7182455/),min,2-5,69364,DB00883,Isosorbide Dinitrate
,7182455,half-life,"Terminal disappearance had a half-life of 67 (62-75) min (mean, range).",Pharmacokinetics of intravenous isosorbide-dinitrate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7182455/),min,67,69365,DB00883,Isosorbide Dinitrate
,7182455,Total plasma clearance,"Total plasma clearance was 1.6 (1.2-2.2) litres X min-1, thus approaching liver blood flow.",Pharmacokinetics of intravenous isosorbide-dinitrate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7182455/),[l] / [min],1.6,69366,DB00883,Isosorbide Dinitrate
,7182455,absolute systemic availability (F),"Nevertheless, absolute systemic availability (F) or oral ISDN amounted to 22% (16-29%).",Pharmacokinetics of intravenous isosorbide-dinitrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7182455/),%,22,69367,DB00883,Isosorbide Dinitrate
,7182455,liver blood flow,"Assuming that oral ISDN is completely absorbed and blood levels do not exceed serum levels, an upper limit of hepatic clearance (liver blood flow 1.5 litres X min-1 X (1-F/100)) can be estimated, which is significantly smaller (p less than 0.05) than the measured clearance.",Pharmacokinetics of intravenous isosorbide-dinitrate. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7182455/),[1-fÂ·l] / [100Â·min],1.5,69368,DB00883,Isosorbide Dinitrate
,8216439,maximum concentrations,Both sprays showed mean maximum concentrations of ISDN in plasma of nearly 18 ng/ml about 7 min after drug intake with arithmetic mean values for the areas under the curve AUC0-12 of 7.01 (test spray) and 7.30 h.ng/ml (reference spray).,Bioavailability and pharmacokinetics of a new isosorbide dinitrate spray preparation in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216439/),[ng] / [ml],18,70534,DB00883,Isosorbide Dinitrate
,8216439,areas under the curve AUC0-12,Both sprays showed mean maximum concentrations of ISDN in plasma of nearly 18 ng/ml about 7 min after drug intake with arithmetic mean values for the areas under the curve AUC0-12 of 7.01 (test spray) and 7.30 h.ng/ml (reference spray).,Bioavailability and pharmacokinetics of a new isosorbide dinitrate spray preparation in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216439/),[hÂ·ng] / [ml],7.01,70535,DB00883,Isosorbide Dinitrate
,8216439,areas under the curve AUC0-12,Both sprays showed mean maximum concentrations of ISDN in plasma of nearly 18 ng/ml about 7 min after drug intake with arithmetic mean values for the areas under the curve AUC0-12 of 7.01 (test spray) and 7.30 h.ng/ml (reference spray).,Bioavailability and pharmacokinetics of a new isosorbide dinitrate spray preparation in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216439/),[hÂ·ng] / [ml],7.30,70536,DB00883,Isosorbide Dinitrate
,8216439,maximum concentrations,"For the metabolic products IS-2-MN and IS-5-MN (values for the reference spray in brackets) the corresponding maximum concentrations were 4.15 (4.21) ng/ml and 16.1 (15.9) ng/ml, respectively, and for the areas under the curve AUC0-12 values of 9.75 (9.92) h.ng/ml for IS-2-MN and 104.3 (99.7) h.ng/ml for IS-5-MN in the mean were calculated.",Bioavailability and pharmacokinetics of a new isosorbide dinitrate spray preparation in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216439/),[ng] / [ml],4.15,70537,DB00883,Isosorbide Dinitrate
,8216439,maximum concentrations,"For the metabolic products IS-2-MN and IS-5-MN (values for the reference spray in brackets) the corresponding maximum concentrations were 4.15 (4.21) ng/ml and 16.1 (15.9) ng/ml, respectively, and for the areas under the curve AUC0-12 values of 9.75 (9.92) h.ng/ml for IS-2-MN and 104.3 (99.7) h.ng/ml for IS-5-MN in the mean were calculated.",Bioavailability and pharmacokinetics of a new isosorbide dinitrate spray preparation in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216439/),[ng] / [ml],16.1,70538,DB00883,Isosorbide Dinitrate
,8216439,areas under the curve AUC0-12,"For the metabolic products IS-2-MN and IS-5-MN (values for the reference spray in brackets) the corresponding maximum concentrations were 4.15 (4.21) ng/ml and 16.1 (15.9) ng/ml, respectively, and for the areas under the curve AUC0-12 values of 9.75 (9.92) h.ng/ml for IS-2-MN and 104.3 (99.7) h.ng/ml for IS-5-MN in the mean were calculated.",Bioavailability and pharmacokinetics of a new isosorbide dinitrate spray preparation in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216439/),[hÂ·ng] / [ml],9.75,70539,DB00883,Isosorbide Dinitrate
,8216439,areas under the curve AUC0-12,"For the metabolic products IS-2-MN and IS-5-MN (values for the reference spray in brackets) the corresponding maximum concentrations were 4.15 (4.21) ng/ml and 16.1 (15.9) ng/ml, respectively, and for the areas under the curve AUC0-12 values of 9.75 (9.92) h.ng/ml for IS-2-MN and 104.3 (99.7) h.ng/ml for IS-5-MN in the mean were calculated.",Bioavailability and pharmacokinetics of a new isosorbide dinitrate spray preparation in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8216439/),[hÂ·ng] / [ml],104.3,70540,DB00883,Isosorbide Dinitrate
,7110964,volume of distribution during steady state (Vd beta,The volume of distribution during steady state (Vd beta = 318 +/- 117 I) and the elimination half-life (t1/2 beta = 64.8 +/- 30.5 min) were similar to those found after perlingual and oral administration.,[Pharmacokinetics of isosorbide dinitrate administered by intravenous infusion to hypertensive patients (author's transl)]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7110964/),i,318,71693,DB00883,Isosorbide Dinitrate
,7110964,elimination half-life (t1/2 beta,The volume of distribution during steady state (Vd beta = 318 +/- 117 I) and the elimination half-life (t1/2 beta = 64.8 +/- 30.5 min) were similar to those found after perlingual and oral administration.,[Pharmacokinetics of isosorbide dinitrate administered by intravenous infusion to hypertensive patients (author's transl)]. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7110964/),min,64.8,71694,DB00883,Isosorbide Dinitrate
,7110964,Systemic clearance (Cls,"Systemic clearance (Cls = 3.80 +/- 1.48 I/min) was high for a drug given intravenously, presumably because of active hepatic extraction, intensive pre-systemic degradation and very active extra-hepatic metabolism.",[Pharmacokinetics of isosorbide dinitrate administered by intravenous infusion to hypertensive patients (author's transl)]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7110964/),[i] / [min],3.80,71695,DB00883,Isosorbide Dinitrate
,7110964,bioavailability ratios,"Comparison of the results obtained by the intravenous route with previously published results after perlingual and oral administration indicates the following bioavailability ratios: perlingual/i.v. = 31%, oral/i.v. = 20%, and oral/perlingual = 63%.",[Pharmacokinetics of isosorbide dinitrate administered by intravenous infusion to hypertensive patients (author's transl)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7110964/),%,31,71696,DB00883,Isosorbide Dinitrate
,7110964,bioavailability ratios,"Comparison of the results obtained by the intravenous route with previously published results after perlingual and oral administration indicates the following bioavailability ratios: perlingual/i.v. = 31%, oral/i.v. = 20%, and oral/perlingual = 63%.",[Pharmacokinetics of isosorbide dinitrate administered by intravenous infusion to hypertensive patients (author's transl)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7110964/),%,20,71697,DB00883,Isosorbide Dinitrate
,7110964,bioavailability ratios,"Comparison of the results obtained by the intravenous route with previously published results after perlingual and oral administration indicates the following bioavailability ratios: perlingual/i.v. = 31%, oral/i.v. = 20%, and oral/perlingual = 63%.",[Pharmacokinetics of isosorbide dinitrate administered by intravenous infusion to hypertensive patients (author's transl)]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7110964/),%,63,71698,DB00883,Isosorbide Dinitrate
,3099808,bioavailability,The results of pharmacokinetic studies show that DNL bioavailability is 491 +/- 240% as compared to conventional oral IDN tablets.,"[Dinitrosorbilong--a new Soviet anti-angina preparation. Its comparative pharmacodynamic, pharmacokinetic and clinical study]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3099808/),%,491,71935,DB00883,Isosorbide Dinitrate
,6737249,peak mean plasma drug concentrations,"When adjusted for dose, the peak mean plasma drug concentrations after oral administration were similar (e.g., 9.2 ng/mL after a 10-mg tablet) and about one-half that obtained after sublingual administration.",Isosorbide dinitrate plasma concentrations and bioavailability in human subjects after administration of standard oral and sublingual formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737249/),[ng] / [ml],9.2,72828,DB00883,Isosorbide Dinitrate
,6737249,half-lives,Drug concentrations declined monoexponentially with mean half-lives ranging from 25-36 min.,Isosorbide dinitrate plasma concentrations and bioavailability in human subjects after administration of standard oral and sublingual formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6737249/),min,25-36,72829,DB00883,Isosorbide Dinitrate
,3569063,loss of bioavailability,The sustained release preparations showed a low loss of bioavailability of 13-19% as compared to the nonretarded standard formulations.,[Bioavailability of delayed-action and non-delayed-action preparations of isosorbide-5-nitrate]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3569063/),%,13-19,73185,DB00883,Isosorbide Dinitrate
,12885396,binding,"In vitro binding of INUdR to bovine serum albumin (BSA) was estimated using an ultrafiltration method to be 65 to 77%, depending on the INUdR concentration.",Biochemical and pharmacokinetic evaluation of a novel pyrimidine nucleoside nitric oxide donor as a potential anticancer/antiviral agent. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12885396/),%,65,73271,DB00883,Isosorbide Dinitrate
,12885396,elimination half-life (T(1/2),"The pharmacokinetics of INUdR following single intravenous bolus and oral doses of INUdR (40 mg/kg) to male Sprague-Dawley rats were characterized by a short elimination half-life (T(1/2) 0.27 h), a large steady-state volume of distribution (V(ss) 0.89 l/kg) and high oral bioavailability (F=0.95).",Biochemical and pharmacokinetic evaluation of a novel pyrimidine nucleoside nitric oxide donor as a potential anticancer/antiviral agent. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12885396/),h,0.27,73272,DB00883,Isosorbide Dinitrate
,12885396,steady-state volume of distribution (V(ss),"The pharmacokinetics of INUdR following single intravenous bolus and oral doses of INUdR (40 mg/kg) to male Sprague-Dawley rats were characterized by a short elimination half-life (T(1/2) 0.27 h), a large steady-state volume of distribution (V(ss) 0.89 l/kg) and high oral bioavailability (F=0.95).",Biochemical and pharmacokinetic evaluation of a novel pyrimidine nucleoside nitric oxide donor as a potential anticancer/antiviral agent. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12885396/),[l] / [kg],0.89,73273,DB00883,Isosorbide Dinitrate
,12885396,oral bioavailability (F,"The pharmacokinetics of INUdR following single intravenous bolus and oral doses of INUdR (40 mg/kg) to male Sprague-Dawley rats were characterized by a short elimination half-life (T(1/2) 0.27 h), a large steady-state volume of distribution (V(ss) 0.89 l/kg) and high oral bioavailability (F=0.95).",Biochemical and pharmacokinetic evaluation of a novel pyrimidine nucleoside nitric oxide donor as a potential anticancer/antiviral agent. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12885396/),,0.95,73274,DB00883,Isosorbide Dinitrate
,15366327,t = 0 = 24 h,"Seven females showed a t = 0 = 24 h (Cmin) plasma concentration that was twice as high as the other 5 females and all the males; 125 +/- 12.2 ng/ml versus 59.3 +/- 9.2 ng/ml, respectively, in females (p < 0.0001) and 56.3 +/- 6.9 ng/ml in males (p < 0.0001).",Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15366327/),[ng] / [ml],125,78384,DB00883,Isosorbide Dinitrate
,15366327,Cmin,"Seven females showed a t = 0 = 24 h (Cmin) plasma concentration that was twice as high as the other 5 females and all the males; 125 +/- 12.2 ng/ml versus 59.3 +/- 9.2 ng/ml, respectively, in females (p < 0.0001) and 56.3 +/- 6.9 ng/ml in males (p < 0.0001).",Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15366327/),[ng] / [ml],125,78385,DB00883,Isosorbide Dinitrate
,15366327,Cmin,"Seven females showed a t = 0 = 24 h (Cmin) plasma concentration that was twice as high as the other 5 females and all the males; 125 +/- 12.2 ng/ml versus 59.3 +/- 9.2 ng/ml, respectively, in females (p < 0.0001) and 56.3 +/- 6.9 ng/ml in males (p < 0.0001).",Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15366327/),[ng] / [ml],59.3,78386,DB00883,Isosorbide Dinitrate
,15366327,Cmin,"Seven females showed a t = 0 = 24 h (Cmin) plasma concentration that was twice as high as the other 5 females and all the males; 125 +/- 12.2 ng/ml versus 59.3 +/- 9.2 ng/ml, respectively, in females (p < 0.0001) and 56.3 +/- 6.9 ng/ml in males (p < 0.0001).",Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15366327/),[ng] / [ml],56.3,78387,DB00883,Isosorbide Dinitrate
,15366327,t(1/2),"With both formulations, females in the n = 7 group had a longer t(1/2) and MRT than females in the n = 5 group, 5.06 +/- 0.76 h, 11.2 +/- 0.55 h versus 4.19 +/- 0.56, 9.40 +/- 0.62 h (p = 0.0057).",Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15366327/),h,5.06,78388,DB00883,Isosorbide Dinitrate
,15366327,MRT,"With both formulations, females in the n = 7 group had a longer t(1/2) and MRT than females in the n = 5 group, 5.06 +/- 0.76 h, 11.2 +/- 0.55 h versus 4.19 +/- 0.56, 9.40 +/- 0.62 h (p = 0.0057).",Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15366327/),h,11.2,78389,DB00883,Isosorbide Dinitrate
,15366327,MRT,"With both formulations, females in the n = 7 group had a longer t(1/2) and MRT than females in the n = 5 group, 5.06 +/- 0.76 h, 11.2 +/- 0.55 h versus 4.19 +/- 0.56, 9.40 +/- 0.62 h (p = 0.0057).",Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15366327/),h,9.40,78390,DB00883,Isosorbide Dinitrate
,1976063,t1/2 alpha,"A three compartment model is used to describe ISDN systemic plasma levels with t1/2 alpha = 7 min, t1/2 beta = 48 min and t1/2 gamma = 7.5 hr.","A pharmacokinetic model for isosorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976063/),min,7,79145,DB00883,Isosorbide Dinitrate
,1976063,t1/2 beta,"A three compartment model is used to describe ISDN systemic plasma levels with t1/2 alpha = 7 min, t1/2 beta = 48 min and t1/2 gamma = 7.5 hr.","A pharmacokinetic model for isosorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976063/),min,48,79146,DB00883,Isosorbide Dinitrate
,1976063,t1/2 gamma,"A three compartment model is used to describe ISDN systemic plasma levels with t1/2 alpha = 7 min, t1/2 beta = 48 min and t1/2 gamma = 7.5 hr.","A pharmacokinetic model for isosorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976063/),h,7.5,79147,DB00883,Isosorbide Dinitrate
,1976063,elimination half-lives,Both IS-2MN and IS-5MN systemic plasma levels can be described by one compartment models with first-order elimination (respective elimination half-lives are 1.9 and 5.1 hr).,"A pharmacokinetic model for isosorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976063/),h,1.9,79148,DB00883,Isosorbide Dinitrate
,1976063,elimination half-lives,Both IS-2MN and IS-5MN systemic plasma levels can be described by one compartment models with first-order elimination (respective elimination half-lives are 1.9 and 5.1 hr).,"A pharmacokinetic model for isosorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976063/),h,5.1,79149,DB00883,Isosorbide Dinitrate
,1976063,central compartment volumes of distribution,"The central compartment volumes of distribution for ISDN, IS-2MN and IS-5MN (116, 57, and 38 liters, respectively) are in agreement with reported literature values.","A pharmacokinetic model for isosorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976063/),l,116,79150,DB00883,Isosorbide Dinitrate
,1976063,central compartment volumes of distribution,"The central compartment volumes of distribution for ISDN, IS-2MN and IS-5MN (116, 57, and 38 liters, respectively) are in agreement with reported literature values.","A pharmacokinetic model for isosorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976063/),l,57,79151,DB00883,Isosorbide Dinitrate
,1976063,central compartment volumes of distribution,"The central compartment volumes of distribution for ISDN, IS-2MN and IS-5MN (116, 57, and 38 liters, respectively) are in agreement with reported literature values.","A pharmacokinetic model for isosorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976063/),l,38,79152,DB00883,Isosorbide Dinitrate
,3440041,BS,"BS of 1074, 815 and 3584 nmol.m2.h/l for ISDN, IS-2-MN and IS-5-MN are equivalent to area ratios of 1, 0.8 and 3.3.",[Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440041/),[hÂ·m2Â·nM] / [l],1074,86239,DB00883,Isosorbide Dinitrate
,3440041,BS,"BS of 1074, 815 and 3584 nmol.m2.h/l for ISDN, IS-2-MN and IS-5-MN are equivalent to area ratios of 1, 0.8 and 3.3.",[Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440041/),[hÂ·m2Â·nM] / [l],815,86240,DB00883,Isosorbide Dinitrate
,3440041,BS,"BS of 1074, 815 and 3584 nmol.m2.h/l for ISDN, IS-2-MN and IS-5-MN are equivalent to area ratios of 1, 0.8 and 3.3.",[Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440041/),[hÂ·m2Â·nM] / [l],3584,86241,DB00883,Isosorbide Dinitrate
,3440041,area ratios,"BS of 1074, 815 and 3584 nmol.m2.h/l for ISDN, IS-2-MN and IS-5-MN are equivalent to area ratios of 1, 0.8 and 3.3.",[Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440041/),,1,86242,DB00883,Isosorbide Dinitrate
,3440041,area ratios,"BS of 1074, 815 and 3584 nmol.m2.h/l for ISDN, IS-2-MN and IS-5-MN are equivalent to area ratios of 1, 0.8 and 3.3.",[Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440041/),,0.8,86243,DB00883,Isosorbide Dinitrate
,3440041,area ratios,"BS of 1074, 815 and 3584 nmol.m2.h/l for ISDN, IS-2-MN and IS-5-MN are equivalent to area ratios of 1, 0.8 and 3.3.",[Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440041/),,3.3,86244,DB00883,Isosorbide Dinitrate
,3440041,molar nitrate concentration,"The molar nitrate concentration including metabolites, however, is comparatively low reaching approximately 60-80 nmol/l.",[Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3440041/),[nM] / [l],60-80,86245,DB00883,Isosorbide Dinitrate
,3360048,apparent elimination half-life,The apparent elimination half-life ranged from 4.7 to 10.1 h.,The effect of food on the absorption of slow-release isosorbide-5-mononitrate tablets. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360048/),h,4.7 to 10.1,90514,DB00883,Isosorbide Dinitrate
,3300979,clearance,"Its clearance is 127 ml/min, volume of distribution 48.5 litres and half-life 4.4 h.",Isosorbide 5-mononitrate pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3300979/),[ml] / [min],127,93648,DB00883,Isosorbide Dinitrate
,3300979,volume of distribution,"Its clearance is 127 ml/min, volume of distribution 48.5 litres and half-life 4.4 h.",Isosorbide 5-mononitrate pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3300979/),l,48.5,93649,DB00883,Isosorbide Dinitrate
,3300979,half-life,"Its clearance is 127 ml/min, volume of distribution 48.5 litres and half-life 4.4 h.",Isosorbide 5-mononitrate pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3300979/),h,4.4,93650,DB00883,Isosorbide Dinitrate
,2681004,denitration rate,"Since denitration is practically the only way of elimination, the denitration rate of the compounds is proportional to their total body clearance, which is 3.2 l/min for ISDN, 0.371 l/min for IS-2-MN and 0.124 l/min for IS-5-MN.",Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2681004/),[l] / [min],3.2,95220,DB00883,Isosorbide Dinitrate
,2681004,denitration rate,"Since denitration is practically the only way of elimination, the denitration rate of the compounds is proportional to their total body clearance, which is 3.2 l/min for ISDN, 0.371 l/min for IS-2-MN and 0.124 l/min for IS-5-MN.",Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2681004/),[l] / [min],0.371,95221,DB00883,Isosorbide Dinitrate
,2681004,denitration rate,"Since denitration is practically the only way of elimination, the denitration rate of the compounds is proportional to their total body clearance, which is 3.2 l/min for ISDN, 0.371 l/min for IS-2-MN and 0.124 l/min for IS-5-MN.",Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2681004/),[l] / [min],0.124,95222,DB00883,Isosorbide Dinitrate
,2681004,total body clearance,"Since denitration is practically the only way of elimination, the denitration rate of the compounds is proportional to their total body clearance, which is 3.2 l/min for ISDN, 0.371 l/min for IS-2-MN and 0.124 l/min for IS-5-MN.",Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2681004/),[l] / [min],3.2,95223,DB00883,Isosorbide Dinitrate
,2681004,total body clearance,"Since denitration is practically the only way of elimination, the denitration rate of the compounds is proportional to their total body clearance, which is 3.2 l/min for ISDN, 0.371 l/min for IS-2-MN and 0.124 l/min for IS-5-MN.",Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2681004/),[l] / [min],0.371,95224,DB00883,Isosorbide Dinitrate
,2681004,total body clearance,"Since denitration is practically the only way of elimination, the denitration rate of the compounds is proportional to their total body clearance, which is 3.2 l/min for ISDN, 0.371 l/min for IS-2-MN and 0.124 l/min for IS-5-MN.",Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2681004/),[l] / [min],0.124,95225,DB00883,Isosorbide Dinitrate
,2681004,terminal elimination half-life,"Their terminal elimination half-life is 63, 108 and 264 min respectively.",Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2681004/),min,63,95226,DB00883,Isosorbide Dinitrate
,2681004,terminal elimination half-life,"Their terminal elimination half-life is 63, 108 and 264 min respectively.",Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2681004/),min,108,95227,DB00883,Isosorbide Dinitrate
,2681004,terminal elimination half-life,"Their terminal elimination half-life is 63, 108 and 264 min respectively.",Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2681004/),min,264,95228,DB00883,Isosorbide Dinitrate
,6666223,bioavailability,The bioavailability of isosorbide dinitrate from this sustained-release formulation was about 90% of that from a standard formulation.,Newer aspects of the pharmacokinetics of organic nitrates. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6666223/),%,90,95629,DB00883,Isosorbide Dinitrate
,6666223,systemic availability,"The systemic availability of the drug after oral doses was 93%, its systemic clearance was 127 ml/min, its volume of distribution was 48.5 liters and its half-life was 4.4 h.",Newer aspects of the pharmacokinetics of organic nitrates. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6666223/),%,93,95630,DB00883,Isosorbide Dinitrate
,6666223,systemic clearance,"The systemic availability of the drug after oral doses was 93%, its systemic clearance was 127 ml/min, its volume of distribution was 48.5 liters and its half-life was 4.4 h.",Newer aspects of the pharmacokinetics of organic nitrates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6666223/),[ml] / [min],127,95631,DB00883,Isosorbide Dinitrate
,6666223,volume of distribution,"The systemic availability of the drug after oral doses was 93%, its systemic clearance was 127 ml/min, its volume of distribution was 48.5 liters and its half-life was 4.4 h.",Newer aspects of the pharmacokinetics of organic nitrates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6666223/),l,48.5,95632,DB00883,Isosorbide Dinitrate
,6666223,half-life,"The systemic availability of the drug after oral doses was 93%, its systemic clearance was 127 ml/min, its volume of distribution was 48.5 liters and its half-life was 4.4 h.",Newer aspects of the pharmacokinetics of organic nitrates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6666223/),h,4.4,95633,DB00883,Isosorbide Dinitrate
,17854237,maximum observed concentrations (C(max)),"In phase B, the maximum observed concentrations (C(max)) were 65.9 +/- 53.9, 28.2 +/- 15.8 and 51.5 +/- 54.3 ng/mL of unchanged hydralazine, and 23.1 +/- 12.3, 21.7 +/- 13.4 and 26.7 +/- 18.7 ng/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[ng] / [ml],65.9,97282,DB00883,Isosorbide Dinitrate
,17854237,maximum observed concentrations (C(max)),"In phase B, the maximum observed concentrations (C(max)) were 65.9 +/- 53.9, 28.2 +/- 15.8 and 51.5 +/- 54.3 ng/mL of unchanged hydralazine, and 23.1 +/- 12.3, 21.7 +/- 13.4 and 26.7 +/- 18.7 ng/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[ng] / [ml],28.2,97283,DB00883,Isosorbide Dinitrate
,17854237,maximum observed concentrations (C(max)),"In phase B, the maximum observed concentrations (C(max)) were 65.9 +/- 53.9, 28.2 +/- 15.8 and 51.5 +/- 54.3 ng/mL of unchanged hydralazine, and 23.1 +/- 12.3, 21.7 +/- 13.4 and 26.7 +/- 18.7 ng/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[ng] / [ml],51.5,97284,DB00883,Isosorbide Dinitrate
,17854237,maximum observed concentrations (C(max)),"In phase B, the maximum observed concentrations (C(max)) were 65.9 +/- 53.9, 28.2 +/- 15.8 and 51.5 +/- 54.3 ng/mL of unchanged hydralazine, and 23.1 +/- 12.3, 21.7 +/- 13.4 and 26.7 +/- 18.7 ng/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[ng] / [ml],23.1,97285,DB00883,Isosorbide Dinitrate
,17854237,maximum observed concentrations (C(max)),"In phase B, the maximum observed concentrations (C(max)) were 65.9 +/- 53.9, 28.2 +/- 15.8 and 51.5 +/- 54.3 ng/mL of unchanged hydralazine, and 23.1 +/- 12.3, 21.7 +/- 13.4 and 26.7 +/- 18.7 ng/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[ng] / [ml],21.7,97286,DB00883,Isosorbide Dinitrate
,17854237,maximum observed concentrations (C(max)),"In phase B, the maximum observed concentrations (C(max)) were 65.9 +/- 53.9, 28.2 +/- 15.8 and 51.5 +/- 54.3 ng/mL of unchanged hydralazine, and 23.1 +/- 12.3, 21.7 +/- 13.4 and 26.7 +/- 18.7 ng/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[ng] / [ml],26.7,97287,DB00883,Isosorbide Dinitrate
,17854237,area under the blood/plasma concentration-time curve (AUC),"The area under the blood/plasma concentration-time curve (AUC) values were 32.6 +/- 13.4, 23.3 +/- 15.1 and 32.6 +/- 18.5 ng x h/mL of hydralazine, and 24.4 +/- 9.0, 24.8 +/- 8.0 and 23.5 +/- 6.3 ng x h/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[hÂ·ng] / [ml],32.6,97288,DB00883,Isosorbide Dinitrate
,17854237,area under the blood/plasma concentration-time curve (AUC),"The area under the blood/plasma concentration-time curve (AUC) values were 32.6 +/- 13.4, 23.3 +/- 15.1 and 32.6 +/- 18.5 ng x h/mL of hydralazine, and 24.4 +/- 9.0, 24.8 +/- 8.0 and 23.5 +/- 6.3 ng x h/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[hÂ·ng] / [ml],23.3,97289,DB00883,Isosorbide Dinitrate
,17854237,area under the blood/plasma concentration-time curve (AUC),"The area under the blood/plasma concentration-time curve (AUC) values were 32.6 +/- 13.4, 23.3 +/- 15.1 and 32.6 +/- 18.5 ng x h/mL of hydralazine, and 24.4 +/- 9.0, 24.8 +/- 8.0 and 23.5 +/- 6.3 ng x h/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[hÂ·ng] / [ml],32.6,97290,DB00883,Isosorbide Dinitrate
,17854237,area under the blood/plasma concentration-time curve (AUC),"The area under the blood/plasma concentration-time curve (AUC) values were 32.6 +/- 13.4, 23.3 +/- 15.1 and 32.6 +/- 18.5 ng x h/mL of hydralazine, and 24.4 +/- 9.0, 24.8 +/- 8.0 and 23.5 +/- 6.3 ng x h/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[hÂ·ng] / [ml],24.4,97291,DB00883,Isosorbide Dinitrate
,17854237,area under the blood/plasma concentration-time curve (AUC),"The area under the blood/plasma concentration-time curve (AUC) values were 32.6 +/- 13.4, 23.3 +/- 15.1 and 32.6 +/- 18.5 ng x h/mL of hydralazine, and 24.4 +/- 9.0, 24.8 +/- 8.0 and 23.5 +/- 6.3 ng x h/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[hÂ·ng] / [ml],24.8,97292,DB00883,Isosorbide Dinitrate
,17854237,area under the blood/plasma concentration-time curve (AUC),"The area under the blood/plasma concentration-time curve (AUC) values were 32.6 +/- 13.4, 23.3 +/- 15.1 and 32.6 +/- 18.5 ng x h/mL of hydralazine, and 24.4 +/- 9.0, 24.8 +/- 8.0 and 23.5 +/- 6.3 ng x h/mL of ISDN for the V-HeFT I, V-HeFT II and A-HeFT formulations, respectively.",Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17854237/),[hÂ·ng] / [ml],23.5,97293,DB00883,Isosorbide Dinitrate
,7448342,steady-state plasma levels,The calculated average steady-state plasma levels were 258 ng ml-1 and 514 ng ml-1 in the two subjects respectively.,Pharmacokinetics of isosorbide dinitrate after intravenous infusion in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7448342/),[ng] / [ml],258,98836,DB00883,Isosorbide Dinitrate
,7448342,steady-state plasma levels,The calculated average steady-state plasma levels were 258 ng ml-1 and 514 ng ml-1 in the two subjects respectively.,Pharmacokinetics of isosorbide dinitrate after intravenous infusion in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7448342/),[ng] / [ml],514,98837,DB00883,Isosorbide Dinitrate
,7448342,half-life of elimination,The half-life of elimination of isosorbide dinitrate after termination of the infusion was 9--10 min.,Pharmacokinetics of isosorbide dinitrate after intravenous infusion in human subjects. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7448342/),min,9--10,98838,DB00883,Isosorbide Dinitrate
,7448342,peak plasma levels,"After oral doses, peak plasma levels of 26.6 ng ml-1 and 12.7 ng ml-1 occurred at 10 min and 20 min in the two subjects respectively.",Pharmacokinetics of isosorbide dinitrate after intravenous infusion in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7448342/),[ng] / [ml],26.6,98839,DB00883,Isosorbide Dinitrate
,7448342,peak plasma levels,"After oral doses, peak plasma levels of 26.6 ng ml-1 and 12.7 ng ml-1 occurred at 10 min and 20 min in the two subjects respectively.",Pharmacokinetics of isosorbide dinitrate after intravenous infusion in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7448342/),[ng] / [ml],12.7,98840,DB00883,Isosorbide Dinitrate
,7448342,elimination half-life,"The terminal half-life of drug after the oral doses was much longer than the elimination half-life (about 10 min), and was associated with the absorption phase.",Pharmacokinetics of isosorbide dinitrate after intravenous infusion in human subjects. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7448342/),min,10,98841,DB00883,Isosorbide Dinitrate
up to,7448342,systemic availability,"The systemic availability of isosorbide dinitrate after the oral doses was up to only 3 per cent of the equal doses infused, indicating that presystemic elimination processes accounted for very large proportions of the oral doses.",Pharmacokinetics of isosorbide dinitrate after intravenous infusion in human subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7448342/),%,3,98842,DB00883,Isosorbide Dinitrate
,7448342,systemic clearances of drug,The systemic clearances of drug after infusion of 0.32 l min-1 and 0.16 l min-1 were unexpectedly low for a drug of reported high liver extraction ratio.,Pharmacokinetics of isosorbide dinitrate after intravenous infusion in human subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7448342/),[l] / [min],0.32,98843,DB00883,Isosorbide Dinitrate
,7448342,systemic clearances of drug,The systemic clearances of drug after infusion of 0.32 l min-1 and 0.16 l min-1 were unexpectedly low for a drug of reported high liver extraction ratio.,Pharmacokinetics of isosorbide dinitrate after intravenous infusion in human subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7448342/),[l] / [min],0.16,98844,DB00883,Isosorbide Dinitrate
,1607003,AUC(o-t),The plasma 5-ISMN concentration-time profile was the same whether 5-ISMN was administered concomitantly with ibopamine or alone [AUC(o-t): 2.24 micrograms.,Investigation of a possible pharmacokinetic interaction between ibopamine and isosorbide-5-mononitrate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607003/),Î¼g,2.24,104283,DB00883,Isosorbide Dinitrate
,3223973,maximum ISDN concentrations,"The means of the individual maximum ISDN concentrations during the complete 2-day treatment amounted to 10.4 ng/ml after the 40 mg capsule, 5.3 ng/ml after the 20 mg capsule and 5.3 ng/ml after the reference tablet.",Comparative pharmacokinetics of isosorbide nitrates after repeated doses of sustained release isosorbide dinitrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3223973/),[ng] / [ml],10.4,104819,DB00883,Isosorbide Dinitrate
,3223973,maximum ISDN concentrations,"The means of the individual maximum ISDN concentrations during the complete 2-day treatment amounted to 10.4 ng/ml after the 40 mg capsule, 5.3 ng/ml after the 20 mg capsule and 5.3 ng/ml after the reference tablet.",Comparative pharmacokinetics of isosorbide nitrates after repeated doses of sustained release isosorbide dinitrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3223973/),[ng] / [ml],5.3,104820,DB00883,Isosorbide Dinitrate
,3223973,bioavailability,"In terms of areas under the curve, the mean bioavailability of the 40 mg sustained release capsule relative to the reference formulation was 198% with respect to ISDN, and 197% both with respect to IS-2-N and IS-5-N.",Comparative pharmacokinetics of isosorbide nitrates after repeated doses of sustained release isosorbide dinitrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3223973/),%,198,104821,DB00883,Isosorbide Dinitrate
,3223973,bioavailability,"In terms of areas under the curve, the mean bioavailability of the 40 mg sustained release capsule relative to the reference formulation was 198% with respect to ISDN, and 197% both with respect to IS-2-N and IS-5-N.",Comparative pharmacokinetics of isosorbide nitrates after repeated doses of sustained release isosorbide dinitrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3223973/),%,197,104822,DB00883,Isosorbide Dinitrate
,7308280,invasion half-life,IS-5-MN is rapidly (invasion half-life 4.1 min) and completely absorbed from the gastro-intestinal tract without any first pass metabolism.,Pharmacokinetics of intravenous and oral isosorbide - 5 - mononitrate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7308280/),min,4.1,104845,DB00883,Isosorbide Dinitrate
,7308280,maximum concentration,The maximum concentration of 480 micrograms/l was reached 1.2 h after oral administration of 20 mg.,Pharmacokinetics of intravenous and oral isosorbide - 5 - mononitrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7308280/),[Î¼g] / [l],480,104846,DB00883,Isosorbide Dinitrate
,7308280,distribution coefficient,"The substance was distributed throughout the total body water (distribution coefficient: 0.62), and was eliminated with a terminal t1/2 of 4.1 and 4.6 h after oral and intravenous administration, respectively.",Pharmacokinetics of intravenous and oral isosorbide - 5 - mononitrate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7308280/),,0.62,104847,DB00883,Isosorbide Dinitrate
,7308280,terminal t1/2,"The substance was distributed throughout the total body water (distribution coefficient: 0.62), and was eliminated with a terminal t1/2 of 4.1 and 4.6 h after oral and intravenous administration, respectively.",Pharmacokinetics of intravenous and oral isosorbide - 5 - mononitrate. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7308280/),h,4.1,104848,DB00883,Isosorbide Dinitrate
,7308280,terminal t1/2,"The substance was distributed throughout the total body water (distribution coefficient: 0.62), and was eliminated with a terminal t1/2 of 4.1 and 4.6 h after oral and intravenous administration, respectively.",Pharmacokinetics of intravenous and oral isosorbide - 5 - mononitrate. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7308280/),h,4.6,104849,DB00883,Isosorbide Dinitrate
,7308280,Total body clearance,Total body clearance was 115ml/min.,Pharmacokinetics of intravenous and oral isosorbide - 5 - mononitrate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7308280/),[ml] / [min],115,104850,DB00883,Isosorbide Dinitrate
,7875187,plasma concentrations,"After 14 days of treatment, the mean plasma concentrations of ISDN and 5-ISMN before drug were 0 and 69 ng.",A new isosorbide dinitrate extended-release formulation: pharmacokinetic and clinical parameters in patients with stable angina pectoris. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875187/),ng,0,105683,DB00883,Isosorbide Dinitrate
,7875187,plasma concentrations,"After 14 days of treatment, the mean plasma concentrations of ISDN and 5-ISMN before drug were 0 and 69 ng.",A new isosorbide dinitrate extended-release formulation: pharmacokinetic and clinical parameters in patients with stable angina pectoris. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7875187/),ng,69,105684,DB00883,Isosorbide Dinitrate
,1867657,Relative bioavailability,Relative bioavailability of the test formulation was calculated as 94% (ISDN) and 96% (IS-5-MN).,[Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867657/),%,94,107608,DB00883,Isosorbide Dinitrate
,1867657,Relative bioavailability,Relative bioavailability of the test formulation was calculated as 94% (ISDN) and 96% (IS-5-MN).,[Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867657/),%,96,107609,DB00883,Isosorbide Dinitrate
,1867657,Maximum plasma concentrations,Maximum plasma concentrations of ISDN (IS-5-MN) were determined for the test preparation as 14.3 +/- 3.1 ng/ml (265 +/- 45 45 ng/ml) and as 22.8 +/- 12.6 ng/ml (287 +/- 59 ng/ml) for the reference product.,[Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867657/),[ng] / [ml],14.3,107610,DB00883,Isosorbide Dinitrate
,1867657,Maximum plasma concentrations,Maximum plasma concentrations of ISDN (IS-5-MN) were determined for the test preparation as 14.3 +/- 3.1 ng/ml (265 +/- 45 45 ng/ml) and as 22.8 +/- 12.6 ng/ml (287 +/- 59 ng/ml) for the reference product.,[Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867657/),[ng] / [ml],265,107611,DB00883,Isosorbide Dinitrate
,1867657,Maximum plasma concentrations,Maximum plasma concentrations of ISDN (IS-5-MN) were determined for the test preparation as 14.3 +/- 3.1 ng/ml (265 +/- 45 45 ng/ml) and as 22.8 +/- 12.6 ng/ml (287 +/- 59 ng/ml) for the reference product.,[Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867657/),[ng] / [ml],22.8,107612,DB00883,Isosorbide Dinitrate
,1867657,Maximum plasma concentrations,Maximum plasma concentrations of ISDN (IS-5-MN) were determined for the test preparation as 14.3 +/- 3.1 ng/ml (265 +/- 45 45 ng/ml) and as 22.8 +/- 12.6 ng/ml (287 +/- 59 ng/ml) for the reference product.,[Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867657/),[ng] / [ml],287,107613,DB00883,Isosorbide Dinitrate
,1867657,HVD,HVD-values were for the test preparation 4.5 +/- 1.3 h (ISDN) and 8.5 +/- 1.3 h (IS-5-MN) and for the reference formulation 3.1 +/- 1.2 h (ISDN) and 8.1 +/- 1.4 (IS-5-MN).,[Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867657/),h,4.5,107614,DB00883,Isosorbide Dinitrate
,1867657,HVD,HVD-values were for the test preparation 4.5 +/- 1.3 h (ISDN) and 8.5 +/- 1.3 h (IS-5-MN) and for the reference formulation 3.1 +/- 1.2 h (ISDN) and 8.1 +/- 1.4 (IS-5-MN).,[Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867657/),h,8.5,107615,DB00883,Isosorbide Dinitrate
,1867657,HVD,HVD-values were for the test preparation 4.5 +/- 1.3 h (ISDN) and 8.5 +/- 1.3 h (IS-5-MN) and for the reference formulation 3.1 +/- 1.2 h (ISDN) and 8.1 +/- 1.4 (IS-5-MN).,[Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867657/),h,3.1,107616,DB00883,Isosorbide Dinitrate
,1867657,HVD,HVD-values were for the test preparation 4.5 +/- 1.3 h (ISDN) and 8.5 +/- 1.3 h (IS-5-MN) and for the reference formulation 3.1 +/- 1.2 h (ISDN) and 8.1 +/- 1.4 (IS-5-MN).,[Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1867657/),,8.1,107617,DB00883,Isosorbide Dinitrate
,7957516,Cmax,After the sublingual spray Cmax was higher (39.0 ng.ml-1) and tmax was shorter (3.9 min) than after the sublingual (22.8 ng.ml-1 and 13.8 min) and peroral (16.9 ng.ml-1 and 25.6 min) tablets.,Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957516/),[ng] / [ml],39.0,111186,DB00883,Isosorbide Dinitrate
,7957516,tmax,After the sublingual spray Cmax was higher (39.0 ng.ml-1) and tmax was shorter (3.9 min) than after the sublingual (22.8 ng.ml-1 and 13.8 min) and peroral (16.9 ng.ml-1 and 25.6 min) tablets.,Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957516/),min,3.9,111187,DB00883,Isosorbide Dinitrate
,7957516,tmax,After the sublingual spray Cmax was higher (39.0 ng.ml-1) and tmax was shorter (3.9 min) than after the sublingual (22.8 ng.ml-1 and 13.8 min) and peroral (16.9 ng.ml-1 and 25.6 min) tablets.,Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957516/),[ng] / [ml],22.8,111188,DB00883,Isosorbide Dinitrate
,7957516,tmax,After the sublingual spray Cmax was higher (39.0 ng.ml-1) and tmax was shorter (3.9 min) than after the sublingual (22.8 ng.ml-1 and 13.8 min) and peroral (16.9 ng.ml-1 and 25.6 min) tablets.,Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957516/),min,13.8,111189,DB00883,Isosorbide Dinitrate
,7957516,tmax,After the sublingual spray Cmax was higher (39.0 ng.ml-1) and tmax was shorter (3.9 min) than after the sublingual (22.8 ng.ml-1 and 13.8 min) and peroral (16.9 ng.ml-1 and 25.6 min) tablets.,Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957516/),[ng] / [ml],16.9,111190,DB00883,Isosorbide Dinitrate
,7957516,tmax,After the sublingual spray Cmax was higher (39.0 ng.ml-1) and tmax was shorter (3.9 min) than after the sublingual (22.8 ng.ml-1 and 13.8 min) and peroral (16.9 ng.ml-1 and 25.6 min) tablets.,Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957516/),min,25.6,111191,DB00883,Isosorbide Dinitrate
,7957516,AUC,"The AUC of ISDN did not differ following any of the three formulations (1031; 879; 997 ng.ml-1.min, for the spray, SL tablet and PO-tablet, respectively).",Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957516/),[minÂ·ng] / [ml],1031,111192,DB00883,Isosorbide Dinitrate
,7957516,AUC,"The AUC of ISDN did not differ following any of the three formulations (1031; 879; 997 ng.ml-1.min, for the spray, SL tablet and PO-tablet, respectively).",Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957516/),[minÂ·ng] / [ml],879,111193,DB00883,Isosorbide Dinitrate
,7957516,AUC,"The AUC of ISDN did not differ following any of the three formulations (1031; 879; 997 ng.ml-1.min, for the spray, SL tablet and PO-tablet, respectively).",Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957516/),[minÂ·ng] / [ml],997,111194,DB00883,Isosorbide Dinitrate
,7957516,relative bioavailability,"Thus, compared to the spray, the relative bioavailability of ISDN was 48% and 28% from the sublingual and peroral tablets, respectively.",Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957516/),%,48,111195,DB00883,Isosorbide Dinitrate
,7957516,relative bioavailability,"Thus, compared to the spray, the relative bioavailability of ISDN was 48% and 28% from the sublingual and peroral tablets, respectively.",Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957516/),%,28,111196,DB00883,Isosorbide Dinitrate
,17044464,urate,"The MTACs of low molecular weight (LMW) solutes in the ISMN period were greater than the placebo period: median urea, 16.7 vs 13.8 ml/min; creatinine (Cr), 7.9 vs 6.9 ml/min; and urate, 6.1 vs 5.5 ml/min (p < 0.05 for all except MTAC of urea).",Effectiveness of oral route isosorbide 5-mononitrate on peritoneal solute and fluid transports in CAPD patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17044464/),,5,112434,DB00883,Isosorbide Dinitrate
,17044464,net ultrafiltration (UF),"Despite the increased peritoneal solute clearance, net ultrafiltration (UF) was unchanged after drug administration, 110 (ISMN group) vs 120 ml (placebo group), (NS).",Effectiveness of oral route isosorbide 5-mononitrate on peritoneal solute and fluid transports in CAPD patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17044464/),ml,110,112435,DB00883,Isosorbide Dinitrate
,17044464,net ultrafiltration (UF),"Despite the increased peritoneal solute clearance, net ultrafiltration (UF) was unchanged after drug administration, 110 (ISMN group) vs 120 ml (placebo group), (NS).",Effectiveness of oral route isosorbide 5-mononitrate on peritoneal solute and fluid transports in CAPD patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17044464/),ml,120,112436,DB00883,Isosorbide Dinitrate
,6543135,bioavailability,"The mean extent of bioavailability of IS-5-MN from the 20 mg, 40 mg and 60 mg sustained-release capsules was 79%, 67% and 70% respectively, of that from the standard-release reference tablets.",[Bioavailability of isosorbide-5-mononitrate from delayed-action formulations]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6543135/),%,79,112507,DB00883,Isosorbide Dinitrate
,6543135,bioavailability,"The mean extent of bioavailability of IS-5-MN from the 20 mg, 40 mg and 60 mg sustained-release capsules was 79%, 67% and 70% respectively, of that from the standard-release reference tablets.",[Bioavailability of isosorbide-5-mononitrate from delayed-action formulations]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6543135/),%,67,112508,DB00883,Isosorbide Dinitrate
,6543135,bioavailability,"The mean extent of bioavailability of IS-5-MN from the 20 mg, 40 mg and 60 mg sustained-release capsules was 79%, 67% and 70% respectively, of that from the standard-release reference tablets.",[Bioavailability of isosorbide-5-mononitrate from delayed-action formulations]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6543135/),%,70,112509,DB00883,Isosorbide Dinitrate
,6543135,bioavailability,"The posterior probability that the bioavailability of IS-5-MN was included within the limits 60%-90% of the reference tablets was 97%, 86% and 95% for the 20 mg, 40 mg and 60 mg sustained-release capsules respectively.",[Bioavailability of isosorbide-5-mononitrate from delayed-action formulations]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6543135/),%,97,112510,DB00883,Isosorbide Dinitrate
,6543135,bioavailability,"The posterior probability that the bioavailability of IS-5-MN was included within the limits 60%-90% of the reference tablets was 97%, 86% and 95% for the 20 mg, 40 mg and 60 mg sustained-release capsules respectively.",[Bioavailability of isosorbide-5-mononitrate from delayed-action formulations]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6543135/),%,86,112511,DB00883,Isosorbide Dinitrate
,6543135,bioavailability,"The posterior probability that the bioavailability of IS-5-MN was included within the limits 60%-90% of the reference tablets was 97%, 86% and 95% for the 20 mg, 40 mg and 60 mg sustained-release capsules respectively.",[Bioavailability of isosorbide-5-mononitrate from delayed-action formulations]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6543135/),%,95,112512,DB00883,Isosorbide Dinitrate
,2060550,tmax,"The pharmacokinetic parameters (Cmax, tmax, AUC, t 1/2) did not differ after morning and after evening dosing, tmax being 5.2 h and 4.9 h, respectively.",Clinical chronopharmacology of oral sustained-release isosorbide-5-mononitrate in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060550/),h,5.2,113518,DB00883,Isosorbide Dinitrate
,2060550,tmax,"The pharmacokinetic parameters (Cmax, tmax, AUC, t 1/2) did not differ after morning and after evening dosing, tmax being 5.2 h and 4.9 h, respectively.",Clinical chronopharmacology of oral sustained-release isosorbide-5-mononitrate in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060550/),h,4.9,113519,DB00883,Isosorbide Dinitrate
,11205739,CL(INT),Simulated PK studies were done using a linear first-pass model with CL(INT) values ranging from 15 L/HR to 900 L/HR.,The role of metabolites in bioequivalency assessment. Highly variable drugs with linear kinetics and first-pass effect. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11205739/),l,15,113761,DB00883,Isosorbide Dinitrate
,11205739,CL(INT),Simulated PK studies were done using a linear first-pass model with CL(INT) values ranging from 15 L/HR to 900 L/HR.,The role of metabolites in bioequivalency assessment. Highly variable drugs with linear kinetics and first-pass effect. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11205739/),l,900,113762,DB00883,Isosorbide Dinitrate
,447513,t1/2,"Following administration of the tablet, serum ISDN concentrations reached a peak of 29 ng/ml at 0.5 h, declined monoexponentially with a t1/2 of 25.5 min, and disappeared after 2 to 3 h.",Serum concentrations of isosorbide dinitrate produced by a sustained-release capsule. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/447513/),min,25.5,116396,DB00883,Isosorbide Dinitrate
,17267147,penetration rate constants,"The in vitro transdermal penetration of both ISDN and BP from the patches displayed a zero-order process, and the penetration rate constants were 7.4 microg/(cm(2)h) for ISDN, and 5.9 microg/(cm(2)h) for BP, respectively.",A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17267147/),[Î¼g] / [cm(2)h],7.4,123504,DB00883,Isosorbide Dinitrate
,17267147,penetration rate constants,"The in vitro transdermal penetration of both ISDN and BP from the patches displayed a zero-order process, and the penetration rate constants were 7.4 microg/(cm(2)h) for ISDN, and 5.9 microg/(cm(2)h) for BP, respectively.",A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17267147/),[Î¼g] / [cm(2)h],5.9,123505,DB00883,Isosorbide Dinitrate
,17267147,absolute bioavailabilities,"After transdermal administration to rabbits, the absolute bioavailabilities were 33.6% for ISDN, and 31.3% for BP, respectively.",A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17267147/),%,33.6,123506,DB00883,Isosorbide Dinitrate
,17267147,absolute bioavailabilities,"After transdermal administration to rabbits, the absolute bioavailabilities were 33.6% for ISDN, and 31.3% for BP, respectively.",A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17267147/),%,31.3,123507,DB00883,Isosorbide Dinitrate
,7295884,peaks of mean concentrations,The peaks of mean concentrations of pindolol were 39.7 ng ml-1 at 1.5 h after administration of 7.5 mg drug in combination with isosorbide dinitrate and 38.0 ng ml-1 at 1 h administration of the drug alone.,Plasma concentrations and bioavailability of isosorbide dinitrate and pindolol from a combination formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295884/),[ng] / [ml],39.7,125256,DB00883,Isosorbide Dinitrate
,7295884,peaks of mean concentrations,The peaks of mean concentrations of pindolol were 39.7 ng ml-1 at 1.5 h after administration of 7.5 mg drug in combination with isosorbide dinitrate and 38.0 ng ml-1 at 1 h administration of the drug alone.,Plasma concentrations and bioavailability of isosorbide dinitrate and pindolol from a combination formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295884/),[ng] / [ml],38.0,125257,DB00883,Isosorbide Dinitrate
,7295884,half-life,Concentrations of pindolol in plasma declined with a half-life of 3 h.,Plasma concentrations and bioavailability of isosorbide dinitrate and pindolol from a combination formulation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295884/),h,3,125258,DB00883,Isosorbide Dinitrate
,1818789,tmax,"After administration of IS-5-MN as an immediate-release tablet, the drug was more rapidly absorbed in the morning (tmax of 0.9 h) than in the evening (tmax of 2.1 h).",Chronopharmacology of oral nitrates in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1818789/),h,0.9,131330,DB00883,Isosorbide Dinitrate
,1818789,tmax,"After administration of IS-5-MN as an immediate-release tablet, the drug was more rapidly absorbed in the morning (tmax of 0.9 h) than in the evening (tmax of 2.1 h).",Chronopharmacology of oral nitrates in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1818789/),h,2.1,131331,DB00883,Isosorbide Dinitrate
,1586375,AUC,The AUC after C (26.9 mumol/l x h) was not significantly different from that for A (25.1 mumol/l x h) and B (26.0 mumol/l x h).,[Biological availability and pharmacodynamics following single oral administration or three different sustained-release isosorbide-5-mononitrate dosage forms]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586375/),[Î¼M] / [hÂ·l],26.9,137873,DB00883,Isosorbide Dinitrate
,1586375,AUC,The AUC after C (26.9 mumol/l x h) was not significantly different from that for A (25.1 mumol/l x h) and B (26.0 mumol/l x h).,[Biological availability and pharmacodynamics following single oral administration or three different sustained-release isosorbide-5-mononitrate dosage forms]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586375/),[Î¼M] / [hÂ·l],25.1,137874,DB00883,Isosorbide Dinitrate
,1586375,AUC,The AUC after C (26.9 mumol/l x h) was not significantly different from that for A (25.1 mumol/l x h) and B (26.0 mumol/l x h).,[Biological availability and pharmacodynamics following single oral administration or three different sustained-release isosorbide-5-mononitrate dosage forms]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586375/),[Î¼M] / [hÂ·l],26.0,137875,DB00883,Isosorbide Dinitrate
,1586375,Maximal plasma concentrations (Cmax),"Maximal plasma concentrations (Cmax) for C (1.90 mumol/l), A (1.91 mumol/l), and B (2.05 mumol/l) were obtained at (tmax) 5.72 h, 4.94 h and 4.72 h, respectively.",[Biological availability and pharmacodynamics following single oral administration or three different sustained-release isosorbide-5-mononitrate dosage forms]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586375/),[Î¼M] / [l],1.90,137876,DB00883,Isosorbide Dinitrate
,1586375,Maximal plasma concentrations (Cmax),"Maximal plasma concentrations (Cmax) for C (1.90 mumol/l), A (1.91 mumol/l), and B (2.05 mumol/l) were obtained at (tmax) 5.72 h, 4.94 h and 4.72 h, respectively.",[Biological availability and pharmacodynamics following single oral administration or three different sustained-release isosorbide-5-mononitrate dosage forms]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586375/),[Î¼M] / [l],1.91,137877,DB00883,Isosorbide Dinitrate
,1586375,Maximal plasma concentrations (Cmax),"Maximal plasma concentrations (Cmax) for C (1.90 mumol/l), A (1.91 mumol/l), and B (2.05 mumol/l) were obtained at (tmax) 5.72 h, 4.94 h and 4.72 h, respectively.",[Biological availability and pharmacodynamics following single oral administration or three different sustained-release isosorbide-5-mononitrate dosage forms]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586375/),[Î¼M] / [l],2.05,137878,DB00883,Isosorbide Dinitrate
,1586375,tmax,"Maximal plasma concentrations (Cmax) for C (1.90 mumol/l), A (1.91 mumol/l), and B (2.05 mumol/l) were obtained at (tmax) 5.72 h, 4.94 h and 4.72 h, respectively.",[Biological availability and pharmacodynamics following single oral administration or three different sustained-release isosorbide-5-mononitrate dosage forms]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586375/),h,5.72,137879,DB00883,Isosorbide Dinitrate
,1586375,tmax,"Maximal plasma concentrations (Cmax) for C (1.90 mumol/l), A (1.91 mumol/l), and B (2.05 mumol/l) were obtained at (tmax) 5.72 h, 4.94 h and 4.72 h, respectively.",[Biological availability and pharmacodynamics following single oral administration or three different sustained-release isosorbide-5-mononitrate dosage forms]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586375/),h,4.94,137880,DB00883,Isosorbide Dinitrate
,1586375,tmax,"Maximal plasma concentrations (Cmax) for C (1.90 mumol/l), A (1.91 mumol/l), and B (2.05 mumol/l) were obtained at (tmax) 5.72 h, 4.94 h and 4.72 h, respectively.",[Biological availability and pharmacodynamics following single oral administration or three different sustained-release isosorbide-5-mononitrate dosage forms]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586375/),h,4.72,137881,DB00883,Isosorbide Dinitrate
,1586375,Mean residence times (MRT),"Mean residence times (MRT) 10.5 h (C), 10.3 h (A), and 10.1 h (B) and plateau-times (duration over which the plasma concentration greater than 0.524 mumol/l) 17.8 h (C), 17.1 h (A), and 17.0 h (B) were not significantly different.",[Biological availability and pharmacodynamics following single oral administration or three different sustained-release isosorbide-5-mononitrate dosage forms]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586375/),h,10.5,137882,DB00883,Isosorbide Dinitrate
,1586375,Mean residence times (MRT),"Mean residence times (MRT) 10.5 h (C), 10.3 h (A), and 10.1 h (B) and plateau-times (duration over which the plasma concentration greater than 0.524 mumol/l) 17.8 h (C), 17.1 h (A), and 17.0 h (B) were not significantly different.",[Biological availability and pharmacodynamics following single oral administration or three different sustained-release isosorbide-5-mononitrate dosage forms]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586375/),h,10.3,137883,DB00883,Isosorbide Dinitrate
,1586375,Mean residence times (MRT),"Mean residence times (MRT) 10.5 h (C), 10.3 h (A), and 10.1 h (B) and plateau-times (duration over which the plasma concentration greater than 0.524 mumol/l) 17.8 h (C), 17.1 h (A), and 17.0 h (B) were not significantly different.",[Biological availability and pharmacodynamics following single oral administration or three different sustained-release isosorbide-5-mononitrate dosage forms]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586375/),h,10.1,137884,DB00883,Isosorbide Dinitrate
,1586375,plateau-times,"Mean residence times (MRT) 10.5 h (C), 10.3 h (A), and 10.1 h (B) and plateau-times (duration over which the plasma concentration greater than 0.524 mumol/l) 17.8 h (C), 17.1 h (A), and 17.0 h (B) were not significantly different.",[Biological availability and pharmacodynamics following single oral administration or three different sustained-release isosorbide-5-mononitrate dosage forms]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586375/),h,17.8,137885,DB00883,Isosorbide Dinitrate
,1586375,plateau-times,"Mean residence times (MRT) 10.5 h (C), 10.3 h (A), and 10.1 h (B) and plateau-times (duration over which the plasma concentration greater than 0.524 mumol/l) 17.8 h (C), 17.1 h (A), and 17.0 h (B) were not significantly different.",[Biological availability and pharmacodynamics following single oral administration or three different sustained-release isosorbide-5-mononitrate dosage forms]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586375/),h,17.1,137886,DB00883,Isosorbide Dinitrate
,1586375,plateau-times,"Mean residence times (MRT) 10.5 h (C), 10.3 h (A), and 10.1 h (B) and plateau-times (duration over which the plasma concentration greater than 0.524 mumol/l) 17.8 h (C), 17.1 h (A), and 17.0 h (B) were not significantly different.",[Biological availability and pharmacodynamics following single oral administration or three different sustained-release isosorbide-5-mononitrate dosage forms]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586375/),h,17.0,137887,DB00883,Isosorbide Dinitrate
,1449102,half-life,"The half-life is approximately 5 hours, the volume of distribution is 0.62 liter/kg, and the systemic clearance is 115 mL/min.",Pharmacokinetics of isosorbide mononitrate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1449102/),h,5,140575,DB00883,Isosorbide Dinitrate
,1449102,volume of distribution,"The half-life is approximately 5 hours, the volume of distribution is 0.62 liter/kg, and the systemic clearance is 115 mL/min.",Pharmacokinetics of isosorbide mononitrate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1449102/),[l] / [kg],0.62,140576,DB00883,Isosorbide Dinitrate
,1449102,systemic clearance,"The half-life is approximately 5 hours, the volume of distribution is 0.62 liter/kg, and the systemic clearance is 115 mL/min.",Pharmacokinetics of isosorbide mononitrate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1449102/),[ml] / [min],115,140577,DB00883,Isosorbide Dinitrate
,12504938,final levels,"Serum levels of isosorbide mononitrate continued to rise up to 360 minutes after isosorbide mononitrate insertion, with mean (SD) final levels of 337 (94) microg/L following isosorbide mononitrate 40 mg and 144 (47) microg/L following isosorbide mononitrate 20 mg, P < 0.01.",Serum profile of isosorbide mononitrate after vaginal administration in the third trimester. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504938/),[Î¼g] / [l],337,145073,DB00883,Isosorbide Dinitrate
,12504938,final levels,"Serum levels of isosorbide mononitrate continued to rise up to 360 minutes after isosorbide mononitrate insertion, with mean (SD) final levels of 337 (94) microg/L following isosorbide mononitrate 40 mg and 144 (47) microg/L following isosorbide mononitrate 20 mg, P < 0.01.",Serum profile of isosorbide mononitrate after vaginal administration in the third trimester. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12504938/),[Î¼g] / [l],144,145074,DB00883,Isosorbide Dinitrate
,6694105,half-life,"The half-life for the distribution phase was about 6 min, for the elimination phase about 1.5 hr.",Pharmacokinetic aspects of isosorbide-5-mononitrate in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6694105/),min,6,156883,DB00883,Isosorbide Dinitrate
,6694105,half-life,"The half-life for the distribution phase was about 6 min, for the elimination phase about 1.5 hr.",Pharmacokinetic aspects of isosorbide-5-mononitrate in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6694105/),h,1.5,156884,DB00883,Isosorbide Dinitrate
,6694105,bioavailability,"From the comparison of the areas under the curve, a bioavailability of 71.5% was estimated.",Pharmacokinetic aspects of isosorbide-5-mononitrate in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6694105/),%,71.5,156885,DB00883,Isosorbide Dinitrate
,6694105,minimum plasma concentration,The minimum plasma concentration for a hemodynamic effect was estimated to be 100 ng/ml.,Pharmacokinetic aspects of isosorbide-5-mononitrate in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6694105/),[ng] / [ml],100,156886,DB00883,Isosorbide Dinitrate
,2354713,maximal plasma concentrations,"The maximal plasma concentrations were about 400 ng/ml and the trough value, lower than 100 ng/ml.",Relationship between pharmacokinetics and hemodynamic tolerance to isosorbide-5-mononitrate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354713/),[ng] / [ml],400,157204,DB00883,Isosorbide Dinitrate
lower,2354713,trough,"The maximal plasma concentrations were about 400 ng/ml and the trough value, lower than 100 ng/ml.",Relationship between pharmacokinetics and hemodynamic tolerance to isosorbide-5-mononitrate. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354713/),[ng] / [ml],100,157205,DB00883,Isosorbide Dinitrate
,2354713,Trough plasma concentrations,Trough plasma concentrations were approximately 300 ng/ml during the entire study period.,Relationship between pharmacokinetics and hemodynamic tolerance to isosorbide-5-mononitrate. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354713/),[ng] / [ml],300,157206,DB00883,Isosorbide Dinitrate
,2354713,trough plasma concentrations,"However, a significant attenuation of the hemodynamic effects was measured on the 5th day, when trough plasma concentrations were between 100 and 230 ng/ml.",Relationship between pharmacokinetics and hemodynamic tolerance to isosorbide-5-mononitrate. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354713/),[ng] / [ml],100 and 230,157207,DB00883,Isosorbide Dinitrate
,6851405,systemic clearance,Mean +/- SD systemic clearance of ISDN was 3.4 +/- 1.4 l/min and volume of distribution (VdSS or Vdarea) about 100 l.,"Isosorbide dinitrate kinetics and dynamics after intravenous, sublingual, and percutaneous dosing in angina. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6851405/),[l] / [min],3.4,160012,DB00883,Isosorbide Dinitrate
,6851405,volume of distribution (VdSS or,Mean +/- SD systemic clearance of ISDN was 3.4 +/- 1.4 l/min and volume of distribution (VdSS or Vdarea) about 100 l.,"Isosorbide dinitrate kinetics and dynamics after intravenous, sublingual, and percutaneous dosing in angina. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6851405/),l,100,160013,DB00883,Isosorbide Dinitrate
,6851405,Vdarea),Mean +/- SD systemic clearance of ISDN was 3.4 +/- 1.4 l/min and volume of distribution (VdSS or Vdarea) about 100 l.,"Isosorbide dinitrate kinetics and dynamics after intravenous, sublingual, and percutaneous dosing in angina. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6851405/),l,100,160014,DB00883,Isosorbide Dinitrate
,6851405,bioavailability,"In six patients, sublingual ISDN (5 mg) was also given and mean bioavailability of 59% (19% to 93%) for this route was determined.","Isosorbide dinitrate kinetics and dynamics after intravenous, sublingual, and percutaneous dosing in angina. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6851405/),%,59,160015,DB00883,Isosorbide Dinitrate
,6851405,steady-state plasma concentrations,"After percutaneous application of a topical formulation (100 mg over an area of 400 cm2), steady-state plasma concentrations at about 7 ng/ml were maintained from 6 to 24 hr.","Isosorbide dinitrate kinetics and dynamics after intravenous, sublingual, and percutaneous dosing in angina. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6851405/),[ng] / [ml],7,160016,DB00883,Isosorbide Dinitrate
,6851405,bioavailability,The bioavailability of the topical application was estimated at 30%.,"Isosorbide dinitrate kinetics and dynamics after intravenous, sublingual, and percutaneous dosing in angina. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6851405/),%,30,160017,DB00883,Isosorbide Dinitrate
,3709643,maximal plasma concentration,The maximal plasma concentration of ISDN 2-7 h after oral administration was higher (14 ng/ml) than has been reported in healthy volunteers.,Isosorbide dinitrate in plasma and dialysate during haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709643/),[ng] / [ml],14,163056,DB00883,Isosorbide Dinitrate
,3709643,clearance,The haemodialyzer clearance of ISDN was 92.4 ml/min at a blood flow of 200 ml/min and dialysate flow of 500 ml/min.,Isosorbide dinitrate in plasma and dialysate during haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709643/),[ml] / [min],92.4,163057,DB00883,Isosorbide Dinitrate
,3709643,blood flow,The haemodialyzer clearance of ISDN was 92.4 ml/min at a blood flow of 200 ml/min and dialysate flow of 500 ml/min.,Isosorbide dinitrate in plasma and dialysate during haemodialysis. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709643/),[ml] / [min],200,163058,DB00883,Isosorbide Dinitrate
,3709643,flow,The haemodialyzer clearance of ISDN was 92.4 ml/min at a blood flow of 200 ml/min and dialysate flow of 500 ml/min.,Isosorbide dinitrate in plasma and dialysate during haemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709643/),[ml] / [min],500,163059,DB00883,Isosorbide Dinitrate
,1472139,recoveries,Intra- and interassay variation coefficients of the gas chromatographic analysis lay between 2.9 and 8.8%; recoveries amounted to 50-62%.,"Pharmacokinetics of the organic nitrates trans-2-amino-2-methyl-N-(4- nitroxycyclohexylmethyl)-propionamide in dogs, and of 4-(2-nitroxyethyl)-piperidine in dogs and in monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1472139/),%,50-62,165818,DB00883,Isosorbide Dinitrate
>,1472139,total bioavailability,"The total bioavailability of BM 12.1200 is > 55%, and that of BM 12.1173 is 63%; their elimination half-lives are, respectively, 4.2 h and 1.3-1.4 h.","Pharmacokinetics of the organic nitrates trans-2-amino-2-methyl-N-(4- nitroxycyclohexylmethyl)-propionamide in dogs, and of 4-(2-nitroxyethyl)-piperidine in dogs and in monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1472139/),%,55,165819,DB00883,Isosorbide Dinitrate
,1472139,total bioavailability,"The total bioavailability of BM 12.1200 is > 55%, and that of BM 12.1173 is 63%; their elimination half-lives are, respectively, 4.2 h and 1.3-1.4 h.","Pharmacokinetics of the organic nitrates trans-2-amino-2-methyl-N-(4- nitroxycyclohexylmethyl)-propionamide in dogs, and of 4-(2-nitroxyethyl)-piperidine in dogs and in monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1472139/),%,63,165820,DB00883,Isosorbide Dinitrate
,1472139,elimination half-lives,"The total bioavailability of BM 12.1200 is > 55%, and that of BM 12.1173 is 63%; their elimination half-lives are, respectively, 4.2 h and 1.3-1.4 h.","Pharmacokinetics of the organic nitrates trans-2-amino-2-methyl-N-(4- nitroxycyclohexylmethyl)-propionamide in dogs, and of 4-(2-nitroxyethyl)-piperidine in dogs and in monkeys. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1472139/),h,4.2,165821,DB00883,Isosorbide Dinitrate
,1472139,elimination half-lives,"The total bioavailability of BM 12.1200 is > 55%, and that of BM 12.1173 is 63%; their elimination half-lives are, respectively, 4.2 h and 1.3-1.4 h.","Pharmacokinetics of the organic nitrates trans-2-amino-2-methyl-N-(4- nitroxycyclohexylmethyl)-propionamide in dogs, and of 4-(2-nitroxyethyl)-piperidine in dogs and in monkeys. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1472139/),h,1.3-1.4,165822,DB00883,Isosorbide Dinitrate
,1472139,elimination half-life (t1/2,"In comparison to all species which have been treated with IS-5-MN thus far, the shortest elimination half-life (t1/2 = 0.6 h) is found in monkeys.","Pharmacokinetics of the organic nitrates trans-2-amino-2-methyl-N-(4- nitroxycyclohexylmethyl)-propionamide in dogs, and of 4-(2-nitroxyethyl)-piperidine in dogs and in monkeys. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1472139/),h,0.6,165823,DB00883,Isosorbide Dinitrate
,3746630,terminal half-life,ISDN concentrations declined with a mean terminal half-life of 2.81 hr +/- 0.7 SD.,Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3746630/),h,2.81,166385,DB00883,Isosorbide Dinitrate
,3746630,systemic clearance,The mean systemic clearance of ISDN (2.9 L/min +/- 0.7 SD) and its mean total volume of distribution (259 L +/- 48 SD) were relatively high.,Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3746630/),[l] / [min],2.9,166386,DB00883,Isosorbide Dinitrate
,3746630,total volume of distribution,The mean systemic clearance of ISDN (2.9 L/min +/- 0.7 SD) and its mean total volume of distribution (259 L +/- 48 SD) were relatively high.,Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3746630/),l,259,166387,DB00883,Isosorbide Dinitrate
,3746630,Maximum levels,Maximum levels of 2-ISMN (6.7 ng/ml +/- 0.9 SD) and of 5-ISMN (27 ng/ml +/- 6 SD) occurred within a few minutes after the end of infusion.,Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3746630/),[ng] / [ml],6.7,166388,DB00883,Isosorbide Dinitrate
,3746630,Maximum levels,Maximum levels of 2-ISMN (6.7 ng/ml +/- 0.9 SD) and of 5-ISMN (27 ng/ml +/- 6 SD) occurred within a few minutes after the end of infusion.,Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3746630/),[ng] / [ml],27,166389,DB00883,Isosorbide Dinitrate
,3746630,half-lives,"The mean half-lives of 2-ISMN (1.59 hr +/- 0.19 SD) and of 5-ISMN (3.78 hr +/- 0.79 SD) estimated by the model were smaller than those calculated by a model-independent method (2.95 hr +/- 0.41 SD and 5.98 hr +/- 2.22, respectively), but were in good agreement with those reported in the literature following separate administration of both metabolites to man.",Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3746630/),h,1.59,166390,DB00883,Isosorbide Dinitrate
,3746630,half-lives,"The mean half-lives of 2-ISMN (1.59 hr +/- 0.19 SD) and of 5-ISMN (3.78 hr +/- 0.79 SD) estimated by the model were smaller than those calculated by a model-independent method (2.95 hr +/- 0.41 SD and 5.98 hr +/- 2.22, respectively), but were in good agreement with those reported in the literature following separate administration of both metabolites to man.",Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3746630/),h,3.78,166391,DB00883,Isosorbide Dinitrate
,3746630,half-lives,"The mean half-lives of 2-ISMN (1.59 hr +/- 0.19 SD) and of 5-ISMN (3.78 hr +/- 0.79 SD) estimated by the model were smaller than those calculated by a model-independent method (2.95 hr +/- 0.41 SD and 5.98 hr +/- 2.22, respectively), but were in good agreement with those reported in the literature following separate administration of both metabolites to man.",Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3746630/),h,2.95,166392,DB00883,Isosorbide Dinitrate
,3746630,half-lives,"The mean half-lives of 2-ISMN (1.59 hr +/- 0.19 SD) and of 5-ISMN (3.78 hr +/- 0.79 SD) estimated by the model were smaller than those calculated by a model-independent method (2.95 hr +/- 0.41 SD and 5.98 hr +/- 2.22, respectively), but were in good agreement with those reported in the literature following separate administration of both metabolites to man.",Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3746630/),h,5.98,166393,DB00883,Isosorbide Dinitrate
,721951,peak,"After application of 100 mg (nominal dose) isosorbide dinitrate as an ointment to the skin of human subjects, mean drug concentrations were 1 to 2 ng/ml for 1.5 hour and reached a peak of 6.2 ng/ml at 6 hours.",Plasma concentrations of isosorbide dinitrate after cutaneous and sublingual doses to human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/721951/),[ng] / [ml],6.2,167251,DB00883,Isosorbide Dinitrate
,721951,concentrations,"Thereafter, mean concentrations declined slowly to 2.9 ng/ml at 12 hours and 1.2 ng/ml at 24 hours.",Plasma concentrations of isosorbide dinitrate after cutaneous and sublingual doses to human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/721951/),[ng] / [ml],2.9,167252,DB00883,Isosorbide Dinitrate
,721951,concentrations,"Thereafter, mean concentrations declined slowly to 2.9 ng/ml at 12 hours and 1.2 ng/ml at 24 hours.",Plasma concentrations of isosorbide dinitrate after cutaneous and sublingual doses to human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/721951/),[ng] / [ml],1.2,167253,DB00883,Isosorbide Dinitrate
,721951,half-life,"After a sublingual dose of 5 mg isosorbide dinitrate, mean drug concentrations reached a peak of 15.9 ng/ml at 0.5 hour and declined with a half-life of about 50 minutes.",Plasma concentrations of isosorbide dinitrate after cutaneous and sublingual doses to human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/721951/),min,50,167254,DB00883,Isosorbide Dinitrate
,721951,bioavailability,The mean bioavailability of isosorbide dinitrate from the ointment was estimated as 30 per cent of that from the sublingual tablet when corrected for differences in dose/body weight ratio.,Plasma concentrations of isosorbide dinitrate after cutaneous and sublingual doses to human subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/721951/),%,30,167255,DB00883,Isosorbide Dinitrate
,582411,peak concentrations,"Means of peak concentrations of 4.2 ng/ml, 13.1 ng/ml, 20.7 ng/ml, 36.8 ng/ml, and 34.9 ng/ml were measured after doses of 20 mg, 40 mg, 60 mg, 80 mg and 100 mg, respectively.",Plasma concentrations of isosorbide dinitrate after administration of increasing doses of a sustained-release formulation to human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582411/),[ng] / [ml],4.2,167711,DB00883,Isosorbide Dinitrate
,582411,peak concentrations,"Means of peak concentrations of 4.2 ng/ml, 13.1 ng/ml, 20.7 ng/ml, 36.8 ng/ml, and 34.9 ng/ml were measured after doses of 20 mg, 40 mg, 60 mg, 80 mg and 100 mg, respectively.",Plasma concentrations of isosorbide dinitrate after administration of increasing doses of a sustained-release formulation to human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582411/),[ng] / [ml],13.1,167712,DB00883,Isosorbide Dinitrate
,582411,peak concentrations,"Means of peak concentrations of 4.2 ng/ml, 13.1 ng/ml, 20.7 ng/ml, 36.8 ng/ml, and 34.9 ng/ml were measured after doses of 20 mg, 40 mg, 60 mg, 80 mg and 100 mg, respectively.",Plasma concentrations of isosorbide dinitrate after administration of increasing doses of a sustained-release formulation to human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582411/),[ng] / [ml],20.7,167713,DB00883,Isosorbide Dinitrate
,582411,peak concentrations,"Means of peak concentrations of 4.2 ng/ml, 13.1 ng/ml, 20.7 ng/ml, 36.8 ng/ml, and 34.9 ng/ml were measured after doses of 20 mg, 40 mg, 60 mg, 80 mg and 100 mg, respectively.",Plasma concentrations of isosorbide dinitrate after administration of increasing doses of a sustained-release formulation to human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582411/),[ng] / [ml],36.8,167714,DB00883,Isosorbide Dinitrate
,582411,peak concentrations,"Means of peak concentrations of 4.2 ng/ml, 13.1 ng/ml, 20.7 ng/ml, 36.8 ng/ml, and 34.9 ng/ml were measured after doses of 20 mg, 40 mg, 60 mg, 80 mg and 100 mg, respectively.",Plasma concentrations of isosorbide dinitrate after administration of increasing doses of a sustained-release formulation to human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582411/),[ng] / [ml],34.9,167715,DB00883,Isosorbide Dinitrate
,576817,peak of mean plasma concentrations,A peak of mean plasma concentrations of isosorbide dinitrate of 5.8 ng/ml was reached at 0.5 h after a single oral dose of 5 mg in a standard tablet formulation.,Plasma concentrations of isosorbide dinitrate after oral administration of a sustained-release formulation to human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/576817/),[ng] / [ml],5.8,175947,DB00883,Isosorbide Dinitrate
,576817,half-life,Thereafter mean concentrations declined with a half-life of about 48 min.,Plasma concentrations of isosorbide dinitrate after oral administration of a sustained-release formulation to human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/576817/),min,48,175948,DB00883,Isosorbide Dinitrate
,576817,peak of mean concentrations,2. A peak of mean concentrations of isosorbide dinitrate of 3.2 ng/ml was reached at 2--4 h after a single oral dose of 20mg in a sustained-realease capsule formulation (Iso Mack Retard).,Plasma concentrations of isosorbide dinitrate after oral administration of a sustained-release formulation to human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/576817/),[ng] / [ml],3.2,175949,DB00883,Isosorbide Dinitrate
,7985521,detection limit,"With a human serum sample size of 200 microliters, the detection limit of IS-5-MN was found to be about 5 ng/ml, and the absolute recovery from 74% to 85%.",[Gas chromatographic method with EC detection to determine isosorbide-5-mononitrate (IS-5-MN) in human serum and its pharmacokinetic parameters]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985521/),[ng] / [ml],5,176166,DB00883,Isosorbide Dinitrate
,7985521,absolute recovery,"With a human serum sample size of 200 microliters, the detection limit of IS-5-MN was found to be about 5 ng/ml, and the absolute recovery from 74% to 85%.",[Gas chromatographic method with EC detection to determine isosorbide-5-mononitrate (IS-5-MN) in human serum and its pharmacokinetic parameters]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985521/),%,74,176167,DB00883,Isosorbide Dinitrate
,7985521,absolute recovery,"With a human serum sample size of 200 microliters, the detection limit of IS-5-MN was found to be about 5 ng/ml, and the absolute recovery from 74% to 85%.",[Gas chromatographic method with EC detection to determine isosorbide-5-mononitrate (IS-5-MN) in human serum and its pharmacokinetic parameters]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7985521/),%,85,176168,DB00883,Isosorbide Dinitrate
,7751425,peak plasma 5-ISMN concentrations,"After administration of the 5-ISMN 60-mg solution, absorption was rapid with mean peak plasma 5-ISMN concentrations of 1533 ng/mL achieved in less than 1 hour.",Effect of food on the oral bioavailability of isosorbide-5-mononitrate administered as an extended-release tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751425/),[ng] / [ml],1533,176351,DB00883,Isosorbide Dinitrate
,7751425,peak plasma concentrations,"In contrast, after administration of IMDUR 60-mg tablets, the drug was more slowly absorbed, reaching mean peak plasma concentrations of 541 ng/mL in 3 to 4 hours.",Effect of food on the oral bioavailability of isosorbide-5-mononitrate administered as an extended-release tablet. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751425/),[ng] / [ml],541,176352,DB00883,Isosorbide Dinitrate
,7751425,bioavailability,"The bioavailability of 5-ISMN from IMDUR tablets under fasted conditions was approximately 78% relative to the solution; and, in the presence of food, the bioavailability was slightly increased to 86% (P = .057).",Effect of food on the oral bioavailability of isosorbide-5-mononitrate administered as an extended-release tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751425/),%,78,176353,DB00883,Isosorbide Dinitrate
,7751425,bioavailability,"The bioavailability of 5-ISMN from IMDUR tablets under fasted conditions was approximately 78% relative to the solution; and, in the presence of food, the bioavailability was slightly increased to 86% (P = .057).",Effect of food on the oral bioavailability of isosorbide-5-mononitrate administered as an extended-release tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751425/),%,86,176354,DB00883,Isosorbide Dinitrate
,7751425,gastric residence time,"The mean gastric residence time of IMDUR tablets under fasted conditions was 68 minutes, and in the presence of food was increased to 478 minutes, with 9 of the 18 subjects having gastric emptying delayed for at least 600 minutes.",Effect of food on the oral bioavailability of isosorbide-5-mononitrate administered as an extended-release tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751425/),min,68,176355,DB00883,Isosorbide Dinitrate
,7751425,gastric residence time,"The mean gastric residence time of IMDUR tablets under fasted conditions was 68 minutes, and in the presence of food was increased to 478 minutes, with 9 of the 18 subjects having gastric emptying delayed for at least 600 minutes.",Effect of food on the oral bioavailability of isosorbide-5-mononitrate administered as an extended-release tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751425/),min,478,176356,DB00883,Isosorbide Dinitrate
,4017416,t1/2,Distribution was rapid; the t1/2 was 4.7 minutes after intravenous injection and 8.7 minutes after sublingual dosing.,"Isosorbide dinitrate bioavailability, kinetics, and metabolism. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017416/),min,4.7,177837,DB00883,Isosorbide Dinitrate
,4017416,t1/2,Distribution was rapid; the t1/2 was 4.7 minutes after intravenous injection and 8.7 minutes after sublingual dosing.,"Isosorbide dinitrate bioavailability, kinetics, and metabolism. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017416/),min,8.7,177838,DB00883,Isosorbide Dinitrate
,4017416,volume of distribution at steady state,The volume of distribution at steady state was 90 L.,"Isosorbide dinitrate bioavailability, kinetics, and metabolism. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017416/),l,90,177839,DB00883,Isosorbide Dinitrate
,4017416,terminal disappearance t1/2,"The terminal disappearance t1/2 was 54.7 minutes after intravenous injection, 48.8 minutes after sublingual dosing, and 47.7 minutes after oral dosing.","Isosorbide dinitrate bioavailability, kinetics, and metabolism. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017416/),min,54.7,177840,DB00883,Isosorbide Dinitrate
,4017416,terminal disappearance t1/2,"The terminal disappearance t1/2 was 54.7 minutes after intravenous injection, 48.8 minutes after sublingual dosing, and 47.7 minutes after oral dosing.","Isosorbide dinitrate bioavailability, kinetics, and metabolism. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017416/),min,48.8,177841,DB00883,Isosorbide Dinitrate
,4017416,terminal disappearance t1/2,"The terminal disappearance t1/2 was 54.7 minutes after intravenous injection, 48.8 minutes after sublingual dosing, and 47.7 minutes after oral dosing.","Isosorbide dinitrate bioavailability, kinetics, and metabolism. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017416/),min,47.7,177842,DB00883,Isosorbide Dinitrate
,4017416,Total plasma clearance,"Total plasma clearance was 136 L/hr, exceeding normal liver plasma flow and indicating extrahepatic metabolism of ISDN.","Isosorbide dinitrate bioavailability, kinetics, and metabolism. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017416/),[l] / [h],136,177843,DB00883,Isosorbide Dinitrate
,4017416,bioavailability,"ISDN bioavailability after oral (10 mg) or sublingual dosing (10 mg) was similar (about 29%), indicating that the first-pass effect cannot be avoided by sublingual ISDN dosing.","Isosorbide dinitrate bioavailability, kinetics, and metabolism. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017416/),%,29,177844,DB00883,Isosorbide Dinitrate
,4017416,terminal t1/2,The terminal t1/2 was 4.33 hours for IS-5-MN and 1.83 hours for IS-2-MN.,"Isosorbide dinitrate bioavailability, kinetics, and metabolism. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017416/),h,4.33,177845,DB00883,Isosorbide Dinitrate
,4017416,terminal t1/2,The terminal t1/2 was 4.33 hours for IS-5-MN and 1.83 hours for IS-2-MN.,"Isosorbide dinitrate bioavailability, kinetics, and metabolism. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4017416/),h,1.83,177846,DB00883,Isosorbide Dinitrate
,9549637,full rate,"min-1.kg-1 ISDN, whereas the full rate of 6 micrograms.",Pharmacokinetics of isosorbide dinitrate in healthy volunteers after 24-hour intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549637/),Î¼g,6,179632,DB00883,Isosorbide Dinitrate
,9549637,Apparent elimination half-lives,"Apparent elimination half-lives of ISDN, IS2MN, and IS5MN were 67 +/- 10 minutes, 115 +/- 13 minutes, and 272 +/- 38 minutes, respectively.",Pharmacokinetics of isosorbide dinitrate in healthy volunteers after 24-hour intravenous infusion. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549637/),min,67,179633,DB00883,Isosorbide Dinitrate
,9549637,Apparent elimination half-lives,"Apparent elimination half-lives of ISDN, IS2MN, and IS5MN were 67 +/- 10 minutes, 115 +/- 13 minutes, and 272 +/- 38 minutes, respectively.",Pharmacokinetics of isosorbide dinitrate in healthy volunteers after 24-hour intravenous infusion. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549637/),min,115,179634,DB00883,Isosorbide Dinitrate
,9549637,Apparent elimination half-lives,"Apparent elimination half-lives of ISDN, IS2MN, and IS5MN were 67 +/- 10 minutes, 115 +/- 13 minutes, and 272 +/- 38 minutes, respectively.",Pharmacokinetics of isosorbide dinitrate in healthy volunteers after 24-hour intravenous infusion. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9549637/),min,272,179635,DB00883,Isosorbide Dinitrate
,12017006,relative bioavailability,"Based on three statistical analyses of the area under the plasma concentration-time curve (AUC), the two tablet formulations are judged to be bioequivalent (P > 0.1), with a relative bioavailability of 108.95% for the IS-5-MN sustained release formulation.",[Multiple dose pharmacokinetic and bioavailability studies of oral sustained release and conventional formulations of isosorbide-5-mononitrate in healthy volunteers]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12017006/),%,108.95,186874,DB00883,Isosorbide Dinitrate
,6491969,oral bioavailability,"At a dose of 2 mg/kg, the oral bioavailability of ISDN was found to be about 40%.",Isosorbide dinitrate disposition in the rat: metabolite pharmacokinetics and interactions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6491969/),%,40,191763,DB00883,Isosorbide Dinitrate
,7439242,elimination half-life,"ISDN was rapidly absorbed and metabolized, having an elimination half-life of 29 min.",Effects and pharmacokinetics of isosorbide dinitrate in normal man. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439242/),min,29,197253,DB00883,Isosorbide Dinitrate
,7439242,half-lives,Its metabolites 2-ISMN and 5-ISMN had longer half-lives of 1.75 and 7.6 h respectively.,Effects and pharmacokinetics of isosorbide dinitrate in normal man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439242/),h,1.75,197254,DB00883,Isosorbide Dinitrate
,7439242,half-lives,Its metabolites 2-ISMN and 5-ISMN had longer half-lives of 1.75 and 7.6 h respectively.,Effects and pharmacokinetics of isosorbide dinitrate in normal man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7439242/),h,7.6,197255,DB00883,Isosorbide Dinitrate
,26716771,relative bioavailability,"The pharmacokinetic study in rats demonstrated that the electrospinning fiber membrane had a higher Cmax and lower Tmax compared to the reference preparation, and the relative bioavailability of the fiber membrane was 151.6%.","A novel application of electrospinning technique in sublingual membrane: characterization, permeation and in vivo study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26716771/),%,151.6,203110,DB00883,Isosorbide Dinitrate
,577507,plasma concentrations,"After sublingual administration of 5 mg of isosorbide dinitrate, mean plasma concentrations (+/-SD) peaked (8.9+/-3.1 ng/ml) at 15 min after dosing and declined with a half-life of 30 min.",Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/577507/),ng,8,203738,DB00883,Isosorbide Dinitrate
,577507,half-life,"After sublingual administration of 5 mg of isosorbide dinitrate, mean plasma concentrations (+/-SD) peaked (8.9+/-3.1 ng/ml) at 15 min after dosing and declined with a half-life of 30 min.",Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/577507/),min,30,203739,DB00883,Isosorbide Dinitrate
,577507,concentrations,"After oral administration of 5 mg, mean concentrations peaked (3.1+/-0.7 ng/ml) at 30 min and declined with a half-life of 40 min.",Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/577507/),[ng] / [ml],3.1,203740,DB00883,Isosorbide Dinitrate
,577507,half-life,"After oral administration of 5 mg, mean concentrations peaked (3.1+/-0.7 ng/ml) at 30 min and declined with a half-life of 40 min.",Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/577507/),min,40,203741,DB00883,Isosorbide Dinitrate
,577507,concentrations,"After oral administration of 20 mg in a sustained-release tablet, mean concentrations initially peaked (1.4+/-1.2 ng/ml) at 40 min, declining to 0.9+/-0.5 ng/ml after 8 hr.",Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/577507/),[ng] / [ml],1.4,203742,DB00883,Isosorbide Dinitrate
,577507,concentrations,"After oral administration of 20 mg in a sustained-release tablet, mean concentrations initially peaked (1.4+/-1.2 ng/ml) at 40 min, declining to 0.9+/-0.5 ng/ml after 8 hr.",Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/577507/),[ng] / [ml],0.9,203743,DB00883,Isosorbide Dinitrate
,577507,bioavailability,"Because of probable rapid first-pass metabolism, the bioavailability of isosorbide dinitrate after administration of the oral dose of the standard tablet was 58% of that from the sublingual dose, and the bioavailability from the sustained-release tablet was 47% of that from the sublingual dose of the standard tablet.",Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/577507/),%,58,203744,DB00883,Isosorbide Dinitrate
,577507,bioavailability,"Because of probable rapid first-pass metabolism, the bioavailability of isosorbide dinitrate after administration of the oral dose of the standard tablet was 58% of that from the sublingual dose, and the bioavailability from the sustained-release tablet was 47% of that from the sublingual dose of the standard tablet.",Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/577507/),%,47,203745,DB00883,Isosorbide Dinitrate
,2610720,maximum plasma concentrations (tmax),Also the moment of maximum plasma concentrations (tmax) occurred significantly later between 2 h 40 min and 3 h 50 min.,[Bioavailability of sustained-release and nonsustained-release isosorbide-5-mononitrate]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610720/),h,2,205218,DB00883,Isosorbide Dinitrate
,2610720,maximum plasma concentrations (tmax),Also the moment of maximum plasma concentrations (tmax) occurred significantly later between 2 h 40 min and 3 h 50 min.,[Bioavailability of sustained-release and nonsustained-release isosorbide-5-mononitrate]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610720/),h,3,205219,DB00883,Isosorbide Dinitrate
,2610720,relative bioavailability,A significant loss in relative bioavailability was observed for (A) with 82.5% and for (C) with 81.4%.,[Bioavailability of sustained-release and nonsustained-release isosorbide-5-mononitrate]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610720/),%,82.5,205220,DB00883,Isosorbide Dinitrate
,2610720,relative bioavailability,A significant loss in relative bioavailability was observed for (A) with 82.5% and for (C) with 81.4%.,[Bioavailability of sustained-release and nonsustained-release isosorbide-5-mononitrate]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610720/),%,81.4,205221,DB00883,Isosorbide Dinitrate
,2610720,relative bioavailability,(B) achieved the highest relative bioavailability (93.9%) of the sustained release preparations (n.s.).,[Bioavailability of sustained-release and nonsustained-release isosorbide-5-mononitrate]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610720/),%,93.9,205222,DB00883,Isosorbide Dinitrate
,2610720,Terminal elimination half-lives,Terminal elimination half-lives were calculated between 5.5 and 6.5 h (mean).,[Bioavailability of sustained-release and nonsustained-release isosorbide-5-mononitrate]. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2610720/),h,5.5 and 6.5,205223,DB00883,Isosorbide Dinitrate
,7250175,duration of action,The duration of action of this dose was approximately 8 h.,First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250175/),h,8,217726,DB00883,Isosorbide Dinitrate
,7250175,maximum concentration,IS-5-MN is rapidly absorbed after oral administration and the maximum concentration in serum was reached 1.2 +/- 0.2 h after doses of 10 to 50 mg.,First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250175/),h,1.2,217727,DB00883,Isosorbide Dinitrate
,7250175,half life,"The compound was eliminated with an average half life of 4.04 +/- 0.16 h, which is appropriate for a reasonably prolonged duration of action without the need for a sustained release formulation.",First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7250175/),h,4.04,217728,DB00883,Isosorbide Dinitrate
,11777752,time to peak (T(max)),"The pharmacokinetics of isosorbide-5-mononitrate after taking the tablet intact or in three fragments were very similar with a mere 10% increase of maximum plasma concentration (C(max)) for the latter, while the time to peak (T(max)) decreased from 5 to 4 h and areas under the concentration vs. time curves (AUCs) were virtually unchanged.",Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777752/),h,5,221746,DB00883,Isosorbide Dinitrate
,11777752,time to peak (T(max)),"The pharmacokinetics of isosorbide-5-mononitrate after taking the tablet intact or in three fragments were very similar with a mere 10% increase of maximum plasma concentration (C(max)) for the latter, while the time to peak (T(max)) decreased from 5 to 4 h and areas under the concentration vs. time curves (AUCs) were virtually unchanged.",Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777752/),h,4,221747,DB00883,Isosorbide Dinitrate
,11777752,Morning trough concentration,"Morning trough concentration reached 53 and 46 ng/ml, respectively.",Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777752/),[ng] / [ml],53,221748,DB00883,Isosorbide Dinitrate
,11777752,Morning trough concentration,"Morning trough concentration reached 53 and 46 ng/ml, respectively.",Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777752/),[ng] / [ml],46,221749,DB00883,Isosorbide Dinitrate
,11777752,T(max),"Administration of the intact tablet after a high-fat breakfast increased C(max) by 18% and AUC by 21%, and slightly delayed T(max) from 5 to 6h.",Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777752/),h,5,221750,DB00883,Isosorbide Dinitrate
,11777752,T(max),"Administration of the intact tablet after a high-fat breakfast increased C(max) by 18% and AUC by 21%, and slightly delayed T(max) from 5 to 6h.",Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777752/),h,6,221751,DB00883,Isosorbide Dinitrate
,11777752,C(max),"During fractional dosing, morning and evening C(max) reached 364 and 315 ng/ml on the first day, and 373 and 300 ng/ml on the 6th day, respectively.",Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777752/),[ng] / [ml],364,221752,DB00883,Isosorbide Dinitrate
,11777752,C(max),"During fractional dosing, morning and evening C(max) reached 364 and 315 ng/ml on the first day, and 373 and 300 ng/ml on the 6th day, respectively.",Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777752/),[ng] / [ml],315,221753,DB00883,Isosorbide Dinitrate
,11777752,C(max),"During fractional dosing, morning and evening C(max) reached 364 and 315 ng/ml on the first day, and 373 and 300 ng/ml on the 6th day, respectively.",Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777752/),[ng] / [ml],373,221754,DB00883,Isosorbide Dinitrate
,11777752,C(max),"During fractional dosing, morning and evening C(max) reached 364 and 315 ng/ml on the first day, and 373 and 300 ng/ml on the 6th day, respectively.",Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777752/),[ng] / [ml],300,221755,DB00883,Isosorbide Dinitrate
,11777752,AUC(0-24 h,"Fractional dosing allows to achieve lower peak and higher morning trough levels, while total exposure is comparable to that during once daily dosing (AUC(0-24 h, s.s.) of 5.55+/-1.78 and 5.71+/-1.08 microg h/ml).",Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777752/),[hÂ·Î¼g] / [ml],5.55,221756,DB00883,Isosorbide Dinitrate
,11777752,AUC(0-24 h,"Fractional dosing allows to achieve lower peak and higher morning trough levels, while total exposure is comparable to that during once daily dosing (AUC(0-24 h, s.s.) of 5.55+/-1.78 and 5.71+/-1.08 microg h/ml).",Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777752/),[hÂ·Î¼g] / [ml],5.71,221757,DB00883,Isosorbide Dinitrate
,1634643,peak plasma levels,"Both preparations led to peak plasma levels of approximately 360 ng/mL IS-5-MN in the mean 0.76 hour (test) and 0.94 hour (reference preparation) after application; the plasma half-lives were about 5.2 hours, and for the areas under the curve (AUC(0-infinity)), mean values of 2741 (test preparation) and 2742 hour.ng/mL (reference preparation) were found.",Evaluation of bioavailability and pharmacokinetics of two isosorbide-5-mononitrate preparations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634643/),[ng] / [ml],360,223471,DB00883,Isosorbide Dinitrate
,1634643,plasma half-lives,"Both preparations led to peak plasma levels of approximately 360 ng/mL IS-5-MN in the mean 0.76 hour (test) and 0.94 hour (reference preparation) after application; the plasma half-lives were about 5.2 hours, and for the areas under the curve (AUC(0-infinity)), mean values of 2741 (test preparation) and 2742 hour.ng/mL (reference preparation) were found.",Evaluation of bioavailability and pharmacokinetics of two isosorbide-5-mononitrate preparations in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634643/),h,5.2,223472,DB00883,Isosorbide Dinitrate
,1634643,areas under the curve (AUC(0-infinity)),"Both preparations led to peak plasma levels of approximately 360 ng/mL IS-5-MN in the mean 0.76 hour (test) and 0.94 hour (reference preparation) after application; the plasma half-lives were about 5.2 hours, and for the areas under the curve (AUC(0-infinity)), mean values of 2741 (test preparation) and 2742 hour.ng/mL (reference preparation) were found.",Evaluation of bioavailability and pharmacokinetics of two isosorbide-5-mononitrate preparations in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634643/),[hÂ·ng] / [ml],2741,223473,DB00883,Isosorbide Dinitrate
,1634643,areas under the curve (AUC(0-infinity)),"Both preparations led to peak plasma levels of approximately 360 ng/mL IS-5-MN in the mean 0.76 hour (test) and 0.94 hour (reference preparation) after application; the plasma half-lives were about 5.2 hours, and for the areas under the curve (AUC(0-infinity)), mean values of 2741 (test preparation) and 2742 hour.ng/mL (reference preparation) were found.",Evaluation of bioavailability and pharmacokinetics of two isosorbide-5-mononitrate preparations in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1634643/),[hÂ·ng] / [ml],2742,223474,DB00883,Isosorbide Dinitrate
,3557738,half-life,"Isosorbide-5-mononitrate is a longer acting active metabolite than the parent drug, isosorbide dinitrate (ISDN), with a half-life of around 4 hours.",Oral isosorbide-5-mononitrate: pharmacokinetics and clinical efficacy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557738/),h,4,226819,DB00883,Isosorbide Dinitrate
,1586374,AUC-ratios,"The metabolism of ISDN differed depending on the route of administration, where the AUC-ratios ISDN: IS-2-MN: IS-5-MN were 1:2.7:19.4 after buccal and 1:5.7:53.4 after oral application respectively.",[Pharmacokinetics of low-dose isosorbide dinitrate and metabolites after buccal or oral administration]. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586374/),,1,228446,DB00883,Isosorbide Dinitrate
,1586374,AUC-ratios,"The metabolism of ISDN differed depending on the route of administration, where the AUC-ratios ISDN: IS-2-MN: IS-5-MN were 1:2.7:19.4 after buccal and 1:5.7:53.4 after oral application respectively.",[Pharmacokinetics of low-dose isosorbide dinitrate and metabolites after buccal or oral administration]. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586374/),,2.7,228447,DB00883,Isosorbide Dinitrate
,1586374,AUC-ratios,"The metabolism of ISDN differed depending on the route of administration, where the AUC-ratios ISDN: IS-2-MN: IS-5-MN were 1:2.7:19.4 after buccal and 1:5.7:53.4 after oral application respectively.",[Pharmacokinetics of low-dose isosorbide dinitrate and metabolites after buccal or oral administration]. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586374/),,19.4,228448,DB00883,Isosorbide Dinitrate
,1586374,AUC-ratios,"The metabolism of ISDN differed depending on the route of administration, where the AUC-ratios ISDN: IS-2-MN: IS-5-MN were 1:2.7:19.4 after buccal and 1:5.7:53.4 after oral application respectively.",[Pharmacokinetics of low-dose isosorbide dinitrate and metabolites after buccal or oral administration]. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586374/),,5.7,228449,DB00883,Isosorbide Dinitrate
,1586374,AUC-ratios,"The metabolism of ISDN differed depending on the route of administration, where the AUC-ratios ISDN: IS-2-MN: IS-5-MN were 1:2.7:19.4 after buccal and 1:5.7:53.4 after oral application respectively.",[Pharmacokinetics of low-dose isosorbide dinitrate and metabolites after buccal or oral administration]. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586374/),,53.4,228450,DB00883,Isosorbide Dinitrate
,2379245,limit of detection,"The reported method is rapid (period of analysis = 10 min), sensitive (limit of detection = 0.1 ng/ml of plasma) and sufficiently precise (error of the method, 12%).",[Determination of isosorbide dinitrate in human plasma after the administration of a newly-developed Czechoslovak preparation]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2379245/),[ng] / [ml],0.1,231179,DB00883,Isosorbide Dinitrate
,3622599,t1/2,"There was significant removal of IS-5-N from blood during HD; Cmax decreased by about 20%, AUC(0-8 h) by 30% and t1/2 by about 20% from 4.3 to 3.4 h, and plasma clearance was increased by 81 ml/min.",Pharmacokinetics of isosorbide-5-nitrate during haemodialysis and peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3622599/),h,4.3,233653,DB00883,Isosorbide Dinitrate
,3622599,t1/2,"There was significant removal of IS-5-N from blood during HD; Cmax decreased by about 20%, AUC(0-8 h) by 30% and t1/2 by about 20% from 4.3 to 3.4 h, and plasma clearance was increased by 81 ml/min.",Pharmacokinetics of isosorbide-5-nitrate during haemodialysis and peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3622599/),h,3.4,233654,DB00883,Isosorbide Dinitrate
,6685489,bioavailability,The bioavailability of IS-2-MN in the rat was 100%.,"[Comparative antianginal, hemodynamic and pharmacokinetic effects of isosorbide-2-mononitrate and isosorbide dinitrate in the rat]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6685489/),%,100,234412,DB00883,Isosorbide Dinitrate
,7738218,AUC,"Compared with oral administration (AUC 2,963 hr x ng/mL, Cmax 442 ng/mL, Tmax 0.81 hr), placement of drug directly into the jejunum did not change the extent (AUC 2,844 hr x ng/mL) but increased the rate of absorption (Cmax 630 ng/mL, Tmax 0.28 hr) due to direct placement of drug into the intestine.",Absorption of isosorbide-5-mononitrate at specific sites in the gastrointestinal tract. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738218/),[hÂ·ng] / [ml],"2,963",235363,DB00883,Isosorbide Dinitrate
,7738218,Cmax,"Compared with oral administration (AUC 2,963 hr x ng/mL, Cmax 442 ng/mL, Tmax 0.81 hr), placement of drug directly into the jejunum did not change the extent (AUC 2,844 hr x ng/mL) but increased the rate of absorption (Cmax 630 ng/mL, Tmax 0.28 hr) due to direct placement of drug into the intestine.",Absorption of isosorbide-5-mononitrate at specific sites in the gastrointestinal tract. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738218/),[ng] / [ml],442,235364,DB00883,Isosorbide Dinitrate
,7738218,Tmax,"Compared with oral administration (AUC 2,963 hr x ng/mL, Cmax 442 ng/mL, Tmax 0.81 hr), placement of drug directly into the jejunum did not change the extent (AUC 2,844 hr x ng/mL) but increased the rate of absorption (Cmax 630 ng/mL, Tmax 0.28 hr) due to direct placement of drug into the intestine.",Absorption of isosorbide-5-mononitrate at specific sites in the gastrointestinal tract. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738218/),h,0.81,235365,DB00883,Isosorbide Dinitrate
,7738218,AUC,"Compared with oral administration (AUC 2,963 hr x ng/mL, Cmax 442 ng/mL, Tmax 0.81 hr), placement of drug directly into the jejunum did not change the extent (AUC 2,844 hr x ng/mL) but increased the rate of absorption (Cmax 630 ng/mL, Tmax 0.28 hr) due to direct placement of drug into the intestine.",Absorption of isosorbide-5-mononitrate at specific sites in the gastrointestinal tract. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738218/),[hÂ·ng] / [ml],"2,844",235366,DB00883,Isosorbide Dinitrate
,7738218,Cmax,"Compared with oral administration (AUC 2,963 hr x ng/mL, Cmax 442 ng/mL, Tmax 0.81 hr), placement of drug directly into the jejunum did not change the extent (AUC 2,844 hr x ng/mL) but increased the rate of absorption (Cmax 630 ng/mL, Tmax 0.28 hr) due to direct placement of drug into the intestine.",Absorption of isosorbide-5-mononitrate at specific sites in the gastrointestinal tract. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738218/),[ng] / [ml],630,235367,DB00883,Isosorbide Dinitrate
,7738218,Tmax,"Compared with oral administration (AUC 2,963 hr x ng/mL, Cmax 442 ng/mL, Tmax 0.81 hr), placement of drug directly into the jejunum did not change the extent (AUC 2,844 hr x ng/mL) but increased the rate of absorption (Cmax 630 ng/mL, Tmax 0.28 hr) due to direct placement of drug into the intestine.",Absorption of isosorbide-5-mononitrate at specific sites in the gastrointestinal tract. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738218/),h,0.28,235368,DB00883,Isosorbide Dinitrate
,7738218,Tmax,"Administration to the terminal ileum resulted in a rate of absorption comparable to that from the jejunum (Tmax 0.28 hr) but a reduction in extent (mean AUC 2,377 hr x ng/mL).",Absorption of isosorbide-5-mononitrate at specific sites in the gastrointestinal tract. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738218/),h,0.28,235369,DB00883,Isosorbide Dinitrate
,7738218,AUC,"Administration to the terminal ileum resulted in a rate of absorption comparable to that from the jejunum (Tmax 0.28 hr) but a reduction in extent (mean AUC 2,377 hr x ng/mL).",Absorption of isosorbide-5-mononitrate at specific sites in the gastrointestinal tract. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738218/),[hÂ·ng] / [ml],"2,377",235370,DB00883,Isosorbide Dinitrate
,7738218,AUC,"Delivery to the ascending colon resulted in a further decrease in the extent (AUC 2,017 hr x ng/mL) and a ""slowing"" of the rate of absorption compared with the two intestinal sites (Cmax 392 ng/mL, Tmax 0.68 hr).",Absorption of isosorbide-5-mononitrate at specific sites in the gastrointestinal tract. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738218/),[hÂ·ng] / [ml],"2,017",235371,DB00883,Isosorbide Dinitrate
,7738218,Cmax,"Delivery to the ascending colon resulted in a further decrease in the extent (AUC 2,017 hr x ng/mL) and a ""slowing"" of the rate of absorption compared with the two intestinal sites (Cmax 392 ng/mL, Tmax 0.68 hr).",Absorption of isosorbide-5-mononitrate at specific sites in the gastrointestinal tract. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738218/),[ng] / [ml],392,235372,DB00883,Isosorbide Dinitrate
,7738218,Tmax,"Delivery to the ascending colon resulted in a further decrease in the extent (AUC 2,017 hr x ng/mL) and a ""slowing"" of the rate of absorption compared with the two intestinal sites (Cmax 392 ng/mL, Tmax 0.68 hr).",Absorption of isosorbide-5-mononitrate at specific sites in the gastrointestinal tract. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7738218/),h,0.68,235373,DB00883,Isosorbide Dinitrate
,11270999,Cmax,The major pharmacokinetic parameters of domestic and imported 5-IM sustained-release capsule with a 5-d multiple dose were respectively: Cmax (677 +/- 103) and (702 +/- 76) micrograms.,Pharmacokinetics of sustained-release capsule of 5-isosorbide mononitrate in 20 healthy Chinese young men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270999/),Î¼g,677,236459,DB00883,Isosorbide Dinitrate
,11270999,Cmax,The major pharmacokinetic parameters of domestic and imported 5-IM sustained-release capsule with a 5-d multiple dose were respectively: Cmax (677 +/- 103) and (702 +/- 76) micrograms.,Pharmacokinetics of sustained-release capsule of 5-isosorbide mononitrate in 20 healthy Chinese young men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270999/),Î¼g,702,236460,DB00883,Isosorbide Dinitrate
,11270999,Tmax,"L-1; Tmax (5.1 +/- 2.0) and (5.6 +/- 1.3) h; MRT (11.5 +/- 0.5) and (11.4 +/- 0.7) h; AUC0-infinity (12,121 +/- 1346) and (12,352 +/- 988) micrograms.",Pharmacokinetics of sustained-release capsule of 5-isosorbide mononitrate in 20 healthy Chinese young men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270999/),h,5.1,236461,DB00883,Isosorbide Dinitrate
,11270999,Tmax,"L-1; Tmax (5.1 +/- 2.0) and (5.6 +/- 1.3) h; MRT (11.5 +/- 0.5) and (11.4 +/- 0.7) h; AUC0-infinity (12,121 +/- 1346) and (12,352 +/- 988) micrograms.",Pharmacokinetics of sustained-release capsule of 5-isosorbide mononitrate in 20 healthy Chinese young men. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270999/),h,5.6,236462,DB00883,Isosorbide Dinitrate
,11270999,MRT,"L-1; Tmax (5.1 +/- 2.0) and (5.6 +/- 1.3) h; MRT (11.5 +/- 0.5) and (11.4 +/- 0.7) h; AUC0-infinity (12,121 +/- 1346) and (12,352 +/- 988) micrograms.",Pharmacokinetics of sustained-release capsule of 5-isosorbide mononitrate in 20 healthy Chinese young men. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270999/),h,11.5,236463,DB00883,Isosorbide Dinitrate
,11270999,MRT,"L-1; Tmax (5.1 +/- 2.0) and (5.6 +/- 1.3) h; MRT (11.5 +/- 0.5) and (11.4 +/- 0.7) h; AUC0-infinity (12,121 +/- 1346) and (12,352 +/- 988) micrograms.",Pharmacokinetics of sustained-release capsule of 5-isosorbide mononitrate in 20 healthy Chinese young men. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270999/),h,11.4,236464,DB00883,Isosorbide Dinitrate
,11270999,AUC0-infinity,"L-1; Tmax (5.1 +/- 2.0) and (5.6 +/- 1.3) h; MRT (11.5 +/- 0.5) and (11.4 +/- 0.7) h; AUC0-infinity (12,121 +/- 1346) and (12,352 +/- 988) micrograms.",Pharmacokinetics of sustained-release capsule of 5-isosorbide mononitrate in 20 healthy Chinese young men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270999/),Î¼g,"12,121",236465,DB00883,Isosorbide Dinitrate
,11270999,AUC0-infinity,"L-1; Tmax (5.1 +/- 2.0) and (5.6 +/- 1.3) h; MRT (11.5 +/- 0.5) and (11.4 +/- 0.7) h; AUC0-infinity (12,121 +/- 1346) and (12,352 +/- 988) micrograms.",Pharmacokinetics of sustained-release capsule of 5-isosorbide mononitrate in 20 healthy Chinese young men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270999/),Î¼g,"12,352",236466,DB00883,Isosorbide Dinitrate
,11270999,relative bioavailability,"The relative bioavailability of the domestic capsule for single and multiple dose were 96% +/- 11% and 98% +/- 10%, respectively.",Pharmacokinetics of sustained-release capsule of 5-isosorbide mononitrate in 20 healthy Chinese young men. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270999/),%,96,236467,DB00883,Isosorbide Dinitrate
,11270999,relative bioavailability,"The relative bioavailability of the domestic capsule for single and multiple dose were 96% +/- 11% and 98% +/- 10%, respectively.",Pharmacokinetics of sustained-release capsule of 5-isosorbide mononitrate in 20 healthy Chinese young men. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11270999/),%,98,236468,DB00883,Isosorbide Dinitrate
,6542370,peak mean level,"Concentrations of 14C reached peak levels at about 1-2 h when about 86% of the 14C was associated with the parent drug, 5-ISMN (peak mean level 430 ng/ml), and the remainder mainly with the pharmacologically-inactive denitrated product isosorbide.",Metabolic fact of 14C-isosorbide 5-mononitrate in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6542370/),[ng] / [ml],430,239346,DB00883,Isosorbide Dinitrate
,6542370,half-life,"Because the plasma (and urinary) half-life of isosorbide was longer (about 8-9 h) than that of 5-ISMN (about 4.5 h), the proportions of the former in plasma increased relative to the latter.",Metabolic fact of 14C-isosorbide 5-mononitrate in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6542370/),h,8-9,239347,DB00883,Isosorbide Dinitrate
,6542370,half-life,"Because the plasma (and urinary) half-life of isosorbide was longer (about 8-9 h) than that of 5-ISMN (about 4.5 h), the proportions of the former in plasma increased relative to the latter.",Metabolic fact of 14C-isosorbide 5-mononitrate in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6542370/),h,4.5,239348,DB00883,Isosorbide Dinitrate
,4013997,oral bioavailability,"In the past few years, convincing data have been obtained in patients showing that intact ISDN is significantly bioavailable to the systemic circulation after oral administration; the oral bioavailability is about 20% relative to an intravenous dose and about 45% relative to a sublingual dose, with the balance metabolized to isosorbide mononitrates.",Pharmacokinetics and pharmacodynamics of isosorbide dinitrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4013997/),%,20,242370,DB00883,Isosorbide Dinitrate
,4013997,oral bioavailability,"In the past few years, convincing data have been obtained in patients showing that intact ISDN is significantly bioavailable to the systemic circulation after oral administration; the oral bioavailability is about 20% relative to an intravenous dose and about 45% relative to a sublingual dose, with the balance metabolized to isosorbide mononitrates.",Pharmacokinetics and pharmacodynamics of isosorbide dinitrate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4013997/),%,45,242371,DB00883,Isosorbide Dinitrate
,11596222,recoveries,The plasma was extracted with a mixture of ethyl ether and n-hexane (4:1) to give mean recoveries of 100.1% of 5-ISMN.,[Determination of isosorbide-5-mononitrate in plasma by GC-ECD and study on its pharmacokinetics in ten volunteers]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596222/),%,100.1,244200,DB00883,Isosorbide Dinitrate
,11596222,detection limit,"The calibration curves were linear over a wide range of concentrations (20-800 ng.ml-1), and the detection limit of 5-ISMN was 2.0 ng.",[Determination of isosorbide-5-mononitrate in plasma by GC-ECD and study on its pharmacokinetics in ten volunteers]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11596222/),ng,2.0,244201,DB00883,Isosorbide Dinitrate
,2751738,AUC0----36h,"For the sustained-release preparation an AUC0----36h of 5764.5 +/- 909 ng/ml.h was measured, an AUC0----infinity of 5863.9 +/- 981.9 ng/ml.h was calculated, with a peak maximum (Cmax) of 472.5 +/- 29.7 ng/ml after 2.9 +/- 0.5 h (tmax).",[Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751738/),[ng] / [hÂ·ml],5764.5,245280,DB00883,Isosorbide Dinitrate
,2751738,AUC0----infinity,"For the sustained-release preparation an AUC0----36h of 5764.5 +/- 909 ng/ml.h was measured, an AUC0----infinity of 5863.9 +/- 981.9 ng/ml.h was calculated, with a peak maximum (Cmax) of 472.5 +/- 29.7 ng/ml after 2.9 +/- 0.5 h (tmax).",[Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751738/),[ng] / [hÂ·ml],5863.9,245281,DB00883,Isosorbide Dinitrate
,2751738,peak maximum (Cmax),"For the sustained-release preparation an AUC0----36h of 5764.5 +/- 909 ng/ml.h was measured, an AUC0----infinity of 5863.9 +/- 981.9 ng/ml.h was calculated, with a peak maximum (Cmax) of 472.5 +/- 29.7 ng/ml after 2.9 +/- 0.5 h (tmax).",[Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751738/),[ng] / [ml],472.5,245282,DB00883,Isosorbide Dinitrate
,2751738,tmax,"For the sustained-release preparation an AUC0----36h of 5764.5 +/- 909 ng/ml.h was measured, an AUC0----infinity of 5863.9 +/- 981.9 ng/ml.h was calculated, with a peak maximum (Cmax) of 472.5 +/- 29.7 ng/ml after 2.9 +/- 0.5 h (tmax).",[Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751738/),h,2.9,245283,DB00883,Isosorbide Dinitrate
,2751738,AUC0----36h,"For the standard-release formulation an AUC0----36h of 5679.8 +/- 690.3 ng/ml.h was measured, an AUC0----infinity of 5688.7 +/- 695.7 ng/ml.h was calculated, with a peak maximum (Cmax) of 842.4 +/- 100.2 ng/ml after 1.2 +/- 0.2 h (tmax).",[Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751738/),[ng] / [hÂ·ml],5679.8,245284,DB00883,Isosorbide Dinitrate
,2751738,AUC0----infinity,"For the standard-release formulation an AUC0----36h of 5679.8 +/- 690.3 ng/ml.h was measured, an AUC0----infinity of 5688.7 +/- 695.7 ng/ml.h was calculated, with a peak maximum (Cmax) of 842.4 +/- 100.2 ng/ml after 1.2 +/- 0.2 h (tmax).",[Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751738/),[ng] / [hÂ·ml],5688.7,245285,DB00883,Isosorbide Dinitrate
,2751738,peak maximum (Cmax),"For the standard-release formulation an AUC0----36h of 5679.8 +/- 690.3 ng/ml.h was measured, an AUC0----infinity of 5688.7 +/- 695.7 ng/ml.h was calculated, with a peak maximum (Cmax) of 842.4 +/- 100.2 ng/ml after 1.2 +/- 0.2 h (tmax).",[Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751738/),[ng] / [ml],842.4,245286,DB00883,Isosorbide Dinitrate
,2751738,tmax,"For the standard-release formulation an AUC0----36h of 5679.8 +/- 690.3 ng/ml.h was measured, an AUC0----infinity of 5688.7 +/- 695.7 ng/ml.h was calculated, with a peak maximum (Cmax) of 842.4 +/- 100.2 ng/ml after 1.2 +/- 0.2 h (tmax).",[Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751738/),h,1.2,245287,DB00883,Isosorbide Dinitrate
,2751738,bioavailability,The bioavailability of the standard-release formulation was postulated to be 100%.,[Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751738/),%,100,245288,DB00883,Isosorbide Dinitrate
,2751738,bioavailability-ratio,The non-parametric calculation of the bioavailability-ratio (geometric Walsh-averages) was 101.47% (95% confidence limits 85.24% to 121.09%).,[Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2751738/),%,101.47,245289,DB00883,Isosorbide Dinitrate
,23093481,total area under the curve (AUCt),"In a bioequivalence study to compare 2 tablets, the mean total area under the curve (AUCt) and peak concentration (Cmax) in the fasted state were 8 476.0 ng Â· h/mL and 540.4 ng/mL, respectively, for the ImdurÂ® Long Acting Tablet 60 mg, and 8 701.4 ng Â· h/mL and 564.2 ng/mL, respectively, for the test tablet.",In vitro dissolution and in vivo bioequivalence evaluation of two brands of isosorbide 5-mononitrate sustained release tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23093481/),[hÂ·ng] / [ml],8 476.0,247276,DB00883,Isosorbide Dinitrate
,23093481,total area under the curve (AUCt),"In a bioequivalence study to compare 2 tablets, the mean total area under the curve (AUCt) and peak concentration (Cmax) in the fasted state were 8 476.0 ng Â· h/mL and 540.4 ng/mL, respectively, for the ImdurÂ® Long Acting Tablet 60 mg, and 8 701.4 ng Â· h/mL and 564.2 ng/mL, respectively, for the test tablet.",In vitro dissolution and in vivo bioequivalence evaluation of two brands of isosorbide 5-mononitrate sustained release tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23093481/),[hÂ·ng] / [ml],8 701.4,247277,DB00883,Isosorbide Dinitrate
,23093481,peak concentration (Cmax),"In a bioequivalence study to compare 2 tablets, the mean total area under the curve (AUCt) and peak concentration (Cmax) in the fasted state were 8 476.0 ng Â· h/mL and 540.4 ng/mL, respectively, for the ImdurÂ® Long Acting Tablet 60 mg, and 8 701.4 ng Â· h/mL and 564.2 ng/mL, respectively, for the test tablet.",In vitro dissolution and in vivo bioequivalence evaluation of two brands of isosorbide 5-mononitrate sustained release tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23093481/),[ng] / [ml],540.4,247278,DB00883,Isosorbide Dinitrate
,23093481,peak concentration (Cmax),"In a bioequivalence study to compare 2 tablets, the mean total area under the curve (AUCt) and peak concentration (Cmax) in the fasted state were 8 476.0 ng Â· h/mL and 540.4 ng/mL, respectively, for the ImdurÂ® Long Acting Tablet 60 mg, and 8 701.4 ng Â· h/mL and 564.2 ng/mL, respectively, for the test tablet.",In vitro dissolution and in vivo bioequivalence evaluation of two brands of isosorbide 5-mononitrate sustained release tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23093481/),[ng] / [ml],564.2,247279,DB00883,Isosorbide Dinitrate
,23093481,AUCt,"The mean AUCt and Cmax in the fed state were 8 793.5 ng Â· h/mL and 559.9 ng/mL, respectively, for the ImdurÂ® Long-Acting tablet 60 mg, and 8 639.8 ng Â· h/mL and 617.9 ng/mL, respectively, for the test tablet.",In vitro dissolution and in vivo bioequivalence evaluation of two brands of isosorbide 5-mononitrate sustained release tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23093481/),[hÂ·ng] / [ml],8 793.5,247280,DB00883,Isosorbide Dinitrate
,23093481,AUCt,"The mean AUCt and Cmax in the fed state were 8 793.5 ng Â· h/mL and 559.9 ng/mL, respectively, for the ImdurÂ® Long-Acting tablet 60 mg, and 8 639.8 ng Â· h/mL and 617.9 ng/mL, respectively, for the test tablet.",In vitro dissolution and in vivo bioequivalence evaluation of two brands of isosorbide 5-mononitrate sustained release tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23093481/),[hÂ·ng] / [ml],8 639.8,247281,DB00883,Isosorbide Dinitrate
,23093481,Cmax,"The mean AUCt and Cmax in the fed state were 8 793.5 ng Â· h/mL and 559.9 ng/mL, respectively, for the ImdurÂ® Long-Acting tablet 60 mg, and 8 639.8 ng Â· h/mL and 617.9 ng/mL, respectively, for the test tablet.",In vitro dissolution and in vivo bioequivalence evaluation of two brands of isosorbide 5-mononitrate sustained release tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23093481/),[ng] / [ml],559.9,247282,DB00883,Isosorbide Dinitrate
,23093481,Cmax,"The mean AUCt and Cmax in the fed state were 8 793.5 ng Â· h/mL and 559.9 ng/mL, respectively, for the ImdurÂ® Long-Acting tablet 60 mg, and 8 639.8 ng Â· h/mL and 617.9 ng/mL, respectively, for the test tablet.",In vitro dissolution and in vivo bioequivalence evaluation of two brands of isosorbide 5-mononitrate sustained release tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23093481/),[ng] / [ml],617.9,247283,DB00883,Isosorbide Dinitrate
,7299675,plasma drug concentrations,"At 2 min after intravenous injection of isosorbide dinitrate (1 mg/kg), mean plasma drug concentrations were 565 +/- 66 (SD), 586 +/- 43, and 1572 +/- 253 ng/ml in the rhesus monkey, cynomolgus monkey, and baboon, respectively.","Pharmacokinetics of isosorbide dinitrate in rhesus monkey, cynomolgus monkey, and baboon. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7299675/),[ng] / [ml],565,249426,DB00883,Isosorbide Dinitrate
,7299675,plasma drug concentrations,"At 2 min after intravenous injection of isosorbide dinitrate (1 mg/kg), mean plasma drug concentrations were 565 +/- 66 (SD), 586 +/- 43, and 1572 +/- 253 ng/ml in the rhesus monkey, cynomolgus monkey, and baboon, respectively.","Pharmacokinetics of isosorbide dinitrate in rhesus monkey, cynomolgus monkey, and baboon. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7299675/),[ng] / [ml],586,249427,DB00883,Isosorbide Dinitrate
,7299675,plasma drug concentrations,"At 2 min after intravenous injection of isosorbide dinitrate (1 mg/kg), mean plasma drug concentrations were 565 +/- 66 (SD), 586 +/- 43, and 1572 +/- 253 ng/ml in the rhesus monkey, cynomolgus monkey, and baboon, respectively.","Pharmacokinetics of isosorbide dinitrate in rhesus monkey, cynomolgus monkey, and baboon. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7299675/),[ng] / [ml],1572,249428,DB00883,Isosorbide Dinitrate
,7299675,half-lives,"Following a relatively short distribution phase, mean plasma concentrations declined with half-lives of 62, 23, and 24 min in these three species, respectively.","Pharmacokinetics of isosorbide dinitrate in rhesus monkey, cynomolgus monkey, and baboon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7299675/),min,62,249429,DB00883,Isosorbide Dinitrate
,7299675,half-lives,"Following a relatively short distribution phase, mean plasma concentrations declined with half-lives of 62, 23, and 24 min in these three species, respectively.","Pharmacokinetics of isosorbide dinitrate in rhesus monkey, cynomolgus monkey, and baboon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7299675/),min,23,249430,DB00883,Isosorbide Dinitrate
,7299675,half-lives,"Following a relatively short distribution phase, mean plasma concentrations declined with half-lives of 62, 23, and 24 min in these three species, respectively.","Pharmacokinetics of isosorbide dinitrate in rhesus monkey, cynomolgus monkey, and baboon. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7299675/),min,24,249431,DB00883,Isosorbide Dinitrate
,6478734,Distribution t 1/2,Distribution t 1/2 was rapid; 8.6 min for IS-5-MN and 12.5 min for IS-2-MN.,Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478734/),min,8.6,249509,DB00883,Isosorbide Dinitrate
,6478734,Distribution t 1/2,Distribution t 1/2 was rapid; 8.6 min for IS-5-MN and 12.5 min for IS-2-MN.,Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478734/),min,12.5,249510,DB00883,Isosorbide Dinitrate
,6478734,volume of distribution at steady state (Vd ss),Substances were distributed throughout body water; volume of distribution at steady state (Vd ss) was 48 l for IS-5-MN and 55 l for IS-2-MN and elimination t 1/2 was 4.15 hr for IS-5-MN and 1.9 hr for IS-2-MN.,Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478734/),l,48,249511,DB00883,Isosorbide Dinitrate
,6478734,volume of distribution at steady state (Vd ss),Substances were distributed throughout body water; volume of distribution at steady state (Vd ss) was 48 l for IS-5-MN and 55 l for IS-2-MN and elimination t 1/2 was 4.15 hr for IS-5-MN and 1.9 hr for IS-2-MN.,Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478734/),l,55,249512,DB00883,Isosorbide Dinitrate
,6478734,elimination t 1/2,Substances were distributed throughout body water; volume of distribution at steady state (Vd ss) was 48 l for IS-5-MN and 55 l for IS-2-MN and elimination t 1/2 was 4.15 hr for IS-5-MN and 1.9 hr for IS-2-MN.,Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478734/),h,4.15,249513,DB00883,Isosorbide Dinitrate
,6478734,elimination t 1/2,Substances were distributed throughout body water; volume of distribution at steady state (Vd ss) was 48 l for IS-5-MN and 55 l for IS-2-MN and elimination t 1/2 was 4.15 hr for IS-5-MN and 1.9 hr for IS-2-MN.,Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478734/),h,1.9,249514,DB00883,Isosorbide Dinitrate
,6478734,Total plasma clearance,Total plasma clearance was 8.5 l/hr for IS-5-MN and 23.2 l/hr for IS-2-MN.,Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478734/),[l] / [h],8.5,249515,DB00883,Isosorbide Dinitrate
,6478734,Total plasma clearance,Total plasma clearance was 8.5 l/hr for IS-5-MN and 23.2 l/hr for IS-2-MN.,Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478734/),[l] / [h],23.2,249516,DB00883,Isosorbide Dinitrate
,6478734,absorption t 1/2,"After oral doses the mononitrates were rapidly and completely absorbed (absorption t 1/2 ranged from 2.5 to 5 min) from the gastrointestinal tract without first-pass metabolism, i.e., absolute systemic availability was 100%.",Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing. ,"t1/2,Î±-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478734/),min,2.5 to 5,249517,DB00883,Isosorbide Dinitrate
,6478734,absolute systemic availability,"After oral doses the mononitrates were rapidly and completely absorbed (absorption t 1/2 ranged from 2.5 to 5 min) from the gastrointestinal tract without first-pass metabolism, i.e., absolute systemic availability was 100%.",Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6478734/),%,100,249518,DB00883,Isosorbide Dinitrate
,6684933,terminal half-life,"The mean concentration-time curve of ISDN showed a peak of 51.6 ng/ml 15 min after drug intake, and declined bi-exponentially with a terminal half-life of 36.5 min.",Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6684933/),min,36.5,251513,DB00883,Isosorbide Dinitrate
,6684933,peaks,"In contrast, after the direct ingestion of isosorbide mononitrates, peaks of 409.1 ng/ml (IS-2-MN) and 483.2 ng/ml (IS-5-MN) were observed in the corresponding mean curves.",Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6684933/),[ng] / [ml],409.1,251514,DB00883,Isosorbide Dinitrate
,6684933,peaks,"In contrast, after the direct ingestion of isosorbide mononitrates, peaks of 409.1 ng/ml (IS-2-MN) and 483.2 ng/ml (IS-5-MN) were observed in the corresponding mean curves.",Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6684933/),[ng] / [ml],483.2,251515,DB00883,Isosorbide Dinitrate
,6684933,half-lives,Mean half-lives of 1.72 h for IS-2-MN and 4.20 h for IS-5-MN were calculated.,Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6684933/),h,1.72,251516,DB00883,Isosorbide Dinitrate
,6684933,half-lives,Mean half-lives of 1.72 h for IS-2-MN and 4.20 h for IS-5-MN were calculated.,Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6684933/),h,4.20,251517,DB00883,Isosorbide Dinitrate
,6684933,apparent volumes of distribution,"The mean apparent volumes of distribution were 44.5 l (IS-2-MN) and 34.4 l (IS-5-MN), suggesting that the isosorbide mononitrates are distributed throughout the whole body fluid.",Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6684933/),l,44.5,251518,DB00883,Isosorbide Dinitrate
,6684933,apparent volumes of distribution,"The mean apparent volumes of distribution were 44.5 l (IS-2-MN) and 34.4 l (IS-5-MN), suggesting that the isosorbide mononitrates are distributed throughout the whole body fluid.",Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6684933/),l,34.4,251519,DB00883,Isosorbide Dinitrate
,1672843,time of peak plasma drug concentration,"Maximum reduction in ST-segment depression was found 4 and 8 h after IS-5-MN intake both after one-week and long-term therapy at the time of peak plasma drug concentration (341 +/- 95 and 405 +/- 125 ng/ml, respectively).","Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672843/),[ng] / [ml],341,256101,DB00883,Isosorbide Dinitrate
,1672843,time of peak plasma drug concentration,"Maximum reduction in ST-segment depression was found 4 and 8 h after IS-5-MN intake both after one-week and long-term therapy at the time of peak plasma drug concentration (341 +/- 95 and 405 +/- 125 ng/ml, respectively).","Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672843/),[ng] / [ml],405,256102,DB00883,Isosorbide Dinitrate
below,1672843,residual plasma concentration,"At a residual plasma concentration below 100 ng/ml, ST depression was not significantly improved 24 h after drug intake compared with placebo.","Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672843/),,100,256103,DB00883,Isosorbide Dinitrate
,1672843,Maximum IS-5-MN plasma concentrations,Maximum IS-5-MN plasma concentrations at a mean of 445 +/- 116 ng/ml were reached after 5.8 +/- 2.9 h.,"Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672843/),[ng] / [ml],445,256104,DB00883,Isosorbide Dinitrate
,1672843,Beta-phase half-life of elimination,Beta-phase half-life of elimination was 9 +/- 3 h.,"Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672843/),h,9,256105,DB00883,Isosorbide Dinitrate
,6414751,half-lives,"These metabolites have a good bioavailability, and half-lives of around 2.5 hours for isosorbide 2-mononitrate and 5 hours for isosorbide 5-mononitrate.",Clinical pharmacokinetics of organic nitrates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6414751/),h,2.5,257793,DB00883,Isosorbide Dinitrate
,6414751,half-lives,"These metabolites have a good bioavailability, and half-lives of around 2.5 hours for isosorbide 2-mononitrate and 5 hours for isosorbide 5-mononitrate.",Clinical pharmacokinetics of organic nitrates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6414751/),h,5,257794,DB00883,Isosorbide Dinitrate
,1810940,detection limits,"With a sample size of 100 microliters of rat plasma, the detection limits were found to be between 0.5 and 2 ng/ml for these mononitrates, and the absolute recovery was found to range from 83 to 90%.",Gas chromatographic analysis of isomeric organic mononitrates in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810940/),[ng] / [ml],0.5 and 2,258549,DB00883,Isosorbide Dinitrate
,1810940,absolute recovery,"With a sample size of 100 microliters of rat plasma, the detection limits were found to be between 0.5 and 2 ng/ml for these mononitrates, and the absolute recovery was found to range from 83 to 90%.",Gas chromatographic analysis of isomeric organic mononitrates in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810940/),%,83 to 90,258550,DB00883,Isosorbide Dinitrate
,1810940,biological half-lives,"The gas chromatographic method was applied to the pharmacokinetic studies of these four isomers in rats; at an intravenous dose of 2 mg/kg, the biological half-lives of L-IIMN, IMMN, IS-2-MN and IS-5-MN were found to be 13.2, 25.2, 54.6 and 112 min, respectively.",Gas chromatographic analysis of isomeric organic mononitrates in plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810940/),min,13.2,258551,DB00883,Isosorbide Dinitrate
,1810940,biological half-lives,"The gas chromatographic method was applied to the pharmacokinetic studies of these four isomers in rats; at an intravenous dose of 2 mg/kg, the biological half-lives of L-IIMN, IMMN, IS-2-MN and IS-5-MN were found to be 13.2, 25.2, 54.6 and 112 min, respectively.",Gas chromatographic analysis of isomeric organic mononitrates in plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810940/),min,25.2,258552,DB00883,Isosorbide Dinitrate
,1810940,biological half-lives,"The gas chromatographic method was applied to the pharmacokinetic studies of these four isomers in rats; at an intravenous dose of 2 mg/kg, the biological half-lives of L-IIMN, IMMN, IS-2-MN and IS-5-MN were found to be 13.2, 25.2, 54.6 and 112 min, respectively.",Gas chromatographic analysis of isomeric organic mononitrates in plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810940/),min,54.6,258553,DB00883,Isosorbide Dinitrate
,1810940,biological half-lives,"The gas chromatographic method was applied to the pharmacokinetic studies of these four isomers in rats; at an intravenous dose of 2 mg/kg, the biological half-lives of L-IIMN, IMMN, IS-2-MN and IS-5-MN were found to be 13.2, 25.2, 54.6 and 112 min, respectively.",Gas chromatographic analysis of isomeric organic mononitrates in plasma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1810940/),min,112,258554,DB00883,Isosorbide Dinitrate
,1790311,plasma half-life,"For both formulations, the mean plasma half-life was found to be approximately 5 h after a single dose.",A combined single and multiple dose pharmacokinetic study of oral isosorbide-5-mononitrate in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1790311/),h,5,260564,DB00883,Isosorbide Dinitrate
,19035874,AUC(tau),"Coadministration of aliskiren and ISMN was associated with only minor changes in the pharmacokinetic parameters of aliskiren (AUC(tau) 1.03 [0.90, 1.18]; C(max) 0.94 [0.69, 1.29]) and ISMN (AUC(tau) 0.88 [0.71, 1.10]; C(max) 0.94 [0.79, 1.13]).",Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19035874/),,1.03,263744,DB00883,Isosorbide Dinitrate
,19035874,C(max),"Coadministration of aliskiren and ISMN was associated with only minor changes in the pharmacokinetic parameters of aliskiren (AUC(tau) 1.03 [0.90, 1.18]; C(max) 0.94 [0.69, 1.29]) and ISMN (AUC(tau) 0.88 [0.71, 1.10]; C(max) 0.94 [0.79, 1.13]).",Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19035874/),,0.94,263745,DB00883,Isosorbide Dinitrate
,19035874,AUC(tau),"Coadministration of aliskiren and ISMN was associated with only minor changes in the pharmacokinetic parameters of aliskiren (AUC(tau) 1.03 [0.90, 1.18]; C(max) 0.94 [0.69, 1.29]) and ISMN (AUC(tau) 0.88 [0.71, 1.10]; C(max) 0.94 [0.79, 1.13]).",Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19035874/),,0.88,263746,DB00883,Isosorbide Dinitrate
,19035874,C(max),"Coadministration of aliskiren and ISMN was associated with only minor changes in the pharmacokinetic parameters of aliskiren (AUC(tau) 1.03 [0.90, 1.18]; C(max) 0.94 [0.69, 1.29]) and ISMN (AUC(tau) 0.88 [0.71, 1.10]; C(max) 0.94 [0.79, 1.13]).",Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19035874/),,0.94,263747,DB00883,Isosorbide Dinitrate
,3905327,relative bioavailability,"The relative bioavailability of ISDN after Iso Mack Retard was 69%, for two development products 78% and 79%, and 87% for Isoket Retard.",[Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3905327/),%,69,265200,DB00883,Isosorbide Dinitrate
,3905327,relative bioavailability,"The relative bioavailability of ISDN after Iso Mack Retard was 69%, for two development products 78% and 79%, and 87% for Isoket Retard.",[Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3905327/),%,78,265201,DB00883,Isosorbide Dinitrate
,3905327,relative bioavailability,"The relative bioavailability of ISDN after Iso Mack Retard was 69%, for two development products 78% and 79%, and 87% for Isoket Retard.",[Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3905327/),%,79,265202,DB00883,Isosorbide Dinitrate
,3905327,relative bioavailability,"The relative bioavailability of ISDN after Iso Mack Retard was 69%, for two development products 78% and 79%, and 87% for Isoket Retard.",[Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3905327/),%,87,265203,DB00883,Isosorbide Dinitrate
,3905327,bioavailability,"The bioavailability of IS-2-MN and IS-5-MN in sustained release preparations was 6-16% and 1-17% lower, respectively.",[Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3905327/),%,6-16,265204,DB00883,Isosorbide Dinitrate
,3905327,bioavailability,"The bioavailability of IS-2-MN and IS-5-MN in sustained release preparations was 6-16% and 1-17% lower, respectively.",[Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3905327/),%,1-17,265205,DB00883,Isosorbide Dinitrate
,3718591,areas under the plasma concentration curve,No significant differences were also found between the areas under the plasma concentration curve (110 vs.,Metabolic fate of the new cardiotonic denopamine in animals. 4th communication: effects of coadministered drugs on the plasma concentration and metabolism of denopamine in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718591/),,110,266181,DB00883,Isosorbide Dinitrate
,3718591,peak plasma concentrations,"127 ng/ml X h, with and without the coadministered drugs, respectively), peak plasma concentrations (32.4 vs. 39.6 ng/ml), times to peak concentration (1.2 vs. 1.0 h) and plasma half-lives (2.2 vs. 2.0 h), respectively.",Metabolic fate of the new cardiotonic denopamine in animals. 4th communication: effects of coadministered drugs on the plasma concentration and metabolism of denopamine in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718591/),[ng] / [ml],32.4,266182,DB00883,Isosorbide Dinitrate
,3718591,peak plasma concentrations,"127 ng/ml X h, with and without the coadministered drugs, respectively), peak plasma concentrations (32.4 vs. 39.6 ng/ml), times to peak concentration (1.2 vs. 1.0 h) and plasma half-lives (2.2 vs. 2.0 h), respectively.",Metabolic fate of the new cardiotonic denopamine in animals. 4th communication: effects of coadministered drugs on the plasma concentration and metabolism of denopamine in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718591/),[ng] / [ml],39.6,266183,DB00883,Isosorbide Dinitrate
,3718591,times to peak concentration,"127 ng/ml X h, with and without the coadministered drugs, respectively), peak plasma concentrations (32.4 vs. 39.6 ng/ml), times to peak concentration (1.2 vs. 1.0 h) and plasma half-lives (2.2 vs. 2.0 h), respectively.",Metabolic fate of the new cardiotonic denopamine in animals. 4th communication: effects of coadministered drugs on the plasma concentration and metabolism of denopamine in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718591/),h,1.2,266184,DB00883,Isosorbide Dinitrate
,3718591,times to peak concentration,"127 ng/ml X h, with and without the coadministered drugs, respectively), peak plasma concentrations (32.4 vs. 39.6 ng/ml), times to peak concentration (1.2 vs. 1.0 h) and plasma half-lives (2.2 vs. 2.0 h), respectively.",Metabolic fate of the new cardiotonic denopamine in animals. 4th communication: effects of coadministered drugs on the plasma concentration and metabolism of denopamine in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718591/),h,1.0,266185,DB00883,Isosorbide Dinitrate
,3718591,plasma half-lives,"127 ng/ml X h, with and without the coadministered drugs, respectively), peak plasma concentrations (32.4 vs. 39.6 ng/ml), times to peak concentration (1.2 vs. 1.0 h) and plasma half-lives (2.2 vs. 2.0 h), respectively.",Metabolic fate of the new cardiotonic denopamine in animals. 4th communication: effects of coadministered drugs on the plasma concentration and metabolism of denopamine in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718591/),h,2.2,266186,DB00883,Isosorbide Dinitrate
,3718591,plasma half-lives,"127 ng/ml X h, with and without the coadministered drugs, respectively), peak plasma concentrations (32.4 vs. 39.6 ng/ml), times to peak concentration (1.2 vs. 1.0 h) and plasma half-lives (2.2 vs. 2.0 h), respectively.",Metabolic fate of the new cardiotonic denopamine in animals. 4th communication: effects of coadministered drugs on the plasma concentration and metabolism of denopamine in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718591/),h,2.0,266187,DB00883,Isosorbide Dinitrate
,7654494,Cmax,"After the initial 30 mg dose on the first day of infarction, mean +/- standard deviation Cmax was 1237 +/- 284 nmol l-1 with a median tmax of 4 h (range 1 to 10 h).",The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654494/),[nM] / [l],1237,269026,DB00883,Isosorbide Dinitrate
,7654494,tmax,"After the initial 30 mg dose on the first day of infarction, mean +/- standard deviation Cmax was 1237 +/- 284 nmol l-1 with a median tmax of 4 h (range 1 to 10 h).",The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654494/),h,4,269027,DB00883,Isosorbide Dinitrate
,7654494,Cmax,"Following the last 60 mg dose, Cmax was 2685 +/- 497 nmol l-1 with a median tmax of 4 h (2 to 7 h).",The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654494/),[nM] / [l],2685,269028,DB00883,Isosorbide Dinitrate
,7654494,tmax,"Following the last 60 mg dose, Cmax was 2685 +/- 497 nmol l-1 with a median tmax of 4 h (2 to 7 h).",The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654494/),h,4,269029,DB00883,Isosorbide Dinitrate
,6124383,half-lives,Concentrations initially declined with similar half-lives (about 1.5 hr) in all three species.,"Metabolic fate of the beta-blocker 14C-bupranolol in humans, dogs, and rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6124383/),h,1.5,270289,DB00883,Isosorbide Dinitrate
